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Summary 
ATP-binding cassette subfamily A member 3 (ABCA3) is a lipid transporter found in 
type II pneumocytes, where it localizes to the outer membrane of lamellar bodies 
(LBs). LBs derive from lysosomal origin and are essential for storing phospholipids 
and surfactant. Mutations in the ABCA3 gene are the most common known genetic 
cause of respiratory distress syndrome (RDS) in newborns and of late onset 
interstitial lung disease (ILD) in children. But the effects of most variations on ABCA3 
protein function are still poorly understood. Therefore we looked in detail at different 
sequence variations of ABCA3 and their impact on wild type function. 
The R288K variation of ABCA3 was found to have an increased frequency in a 
population of patients suffering from ILD. These patients did not exhibit characteristic 
features of complete ABCA3 deficiency. Nevertheless, we found strong evidence that 
R288K variation affects transport function of ABCA3 protein, supported by 
decelerated detoxification of doxorubicin, reduced dipalmitoyl-phosphatidylcholine 
(PC 32:0) content, and decreased LB volume. 
By contrast, the K1388N variation recently found in a patient suffering from ILD with 
lethal outcome led to complete ABCA3 deficiency. We showed that this sequence 
variation of ABCA3 correctly localized to LBs but had a processing defect and a 
reduced lipid transporter activity, proven by reduced PC 32:0 content and malformed 
LBs. 
Due to existent intracellular processing defects of K1388N sequence variation and 
other mutations, we particularly looked at potential protease(s) cleaving ABCA3. An 
identification of these specific proteins may represent a potential therapeutic target. 
We found that ABCA3 is proteolytically cleaved by cathepsin L and to a lower level 
by cathepsin B. Furthermore, we identified the exact cleavage site of cathepsin L 
located after Lys174 in the ABCA3 protein.  
In summary, the molecular tools used in these studies, together with a close 
correlation of our in-vitro and ex-vivo data will allow a better knowledge of ABCA3 
wild type function. Besides this, groups of mutations with similar molecular defects 
can be defined and targeted by specific small molecule correctors for restoring 
impaired ABCA3 transporter function in the future. 
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Zusammenfassung 
ATP-binding cassette subfamily A member 3 (ABCA3) ist ein Lipidtransporter, der in 
alveolären Typ II-Pneumozyten in der äußeren Membran der Lamellarkörpcherchen 
(LBs) zu finden ist. Lamellarkörperchen sind lysosomalen Ursprungs und ein 
essentielles Organell zur Speicherung von Phospholipiden und Surfactant. 
Mutationen in der kodierenden Sequenz des ABCA3-Gens sind die Hauptursache für 
das erblich bedingte Atemnotsyndrom (RDS) bei Neugeborenen und für interstitielle 
Lungenerkrankungen (ILD) bei Kleinkindern. Dennoch sind die Auswirkungen vieler 
ABCA3-Sequenzvariationen weitgehend unbekannt. Deshalb war es unser Ziel, den 
Einfluss verschiedener ABCA3-Mutationen auf die Wildtypfunktion des Proteins zu 
untersuchen. 
Wir konnten zeigen, dass die ABCA3-Variation R288K gehäuft in einer 
Patientengruppe mit ILD vorkommt. Diese Patienten zeigten nicht die üblichen 
Symptome einer kompletten ABCA3-Defizienz. Trotzdem fanden wir starke Hinweise 
darauf, dass die R288K-Variation des ABCA3-Proteins dessen Transportfunktion 
beeinflusst. Diese ging mit einer verlangsamten Detoxifizierung von Doxorubicin, 
einem reduzierten Dipalmitoylphosphatidylcholin (PC 32:0)-Gehalt und einem 
verminderten LB-Volumen einher. 
Im Gegensatz dazu führte die K1388N-Variation, die kürzlich in einem Patienten, der 
an ILD erkrankte und verstarb, entdeckt wurde, zu einer völligen ABCA3-Defizienz. 
Wir konnten zeigen, dass diese ABCA3-Sequenzvariation zwar richtig in LBs 
lokalisiert, aber einen Prozessierungsdefekt und einen verminderten Lipidtransport 
aufwies, welche durch einen reduzierten PC 32:0-Gehalt und deformierte LBs 
nachgewiesen worden konnten. 
Aufgrund des intrazellulären Prozessierungsdefekts der K1388N-Sequenzvariation 
und vieler anderer Mutationen fokussierten wir uns genauer auf mögliche 
Protease(n), die ABCA3 spalten können. Eine Identifikation dieser spezifischen 
Proteine könnte ein mögliches therapeutisches Ziel darstellen. Wir konnten zeigen, 
dass ABCA3 durch Cathepsin L und zu einem geringeren Anteil durch Cathepsin B 
proteolytisch gespalten wird. Zusätzlich konnten wir die genaue Spaltstelle von 
Cathepsin L identifizieren, die sich hinter dem Lys174 im ABCA3-Protein befindet. 
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Zusammenfassend kann man sagen, dass die hier verwendeten 
molekularbiologischen Methoden zusammen mit den von uns erhobenen in-vitro- 
und ex-vivo-Daten ein besseres Verständnis für die Wildtypfunktion des ABCA3-
Proteins aufzeigen. Außerdem können dadurch Mutationen mit ähnlichen 
molekularen Defekten definiert und gruppiert werden, um in Zukunft die durch 
Sequenzvariationen verursachte eingeschränkte Transportfunktion von ABCA3 mit 
spezifischen Korrektoren wiederherzustellen.  
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1. Introduction  
1.1. Interstitial lung diseases in children 
Interstitial lung diseases (ILD) also referred to as diffuse parenchymal lung diseases 
(DPLD), encompass a huge heterogeneous group of chronic respiratory disorders 
leading to dysfunction of gas exchange and restrictive lung physiology [1]. This entity 
involves the distal air spaces as well as the interstitium consisting of connective 
tissue elements, extracellular matrix structures with complex polysaccharides, and 
small numbers of cells such as macrophages [2]. 
ILD is reported in childhood and adults, although prognosis, causes, and severity 
vary in a great manner [3,4]. Idiopathic pulmonary fibrosis (IPF) displays the most 
prominent ILD in adults and is not diagnosed in children [5]. In addition, 
desquamative interstitial pneumonitis (DIP) occurs in both children and adults, but 
differs in clinical and histological features and shows better prognosis in adulthood 
[6]. The main causes and the molecular pathways of ILD development are still poorly 
understood, and further studies have to be performed assuring further insights into 
each entity [7-9]. 
1.2. Pulmonary surfactant and surfactant dysfunction disorders 
The respiratory tract represents a complex biological system consisting of 300 million 
alveolar sacs, which ensure gas exchange of oxygen and carbon dioxide [10]. The 
alveolar epithelium is lined by two different cell types, the alveolar type I and type II 
pneumocytes (AT I or II respectively, Figure 1 A) [11]. The flattened, non-dividing AT 
I cells constitute 90% of the alveolar surface and facilitate gas exchange, while the 
cuboidal AT II cells play an important role in alveolar homeostasis [12]. Therefore, 
AT II cells produce, store, and secret pulmonary surfactant into the alveolar space 
[13]. Once secreted, the surfactant rapidly spreads across the alveolar surface and 
forms a monolayer at the gaseous-aqueous interface in order to lower surface 
tension and prevent alveolar collapse at the end of expiration [14,15].  
Surfactant is a heterogenous mixture of lipids (90%) and proteins (10%) [16]. Most of 
the lipids are phospholipids (PL), mainly phosphatidylcholine (PC), dipalmityol-
phosphatidylcholine (PC 32:0), phosphatidylglycerol (PG), phosphatidylinositol (PI), 
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phosphatidylethanolamine (PE), phosphatidylserine (PS), and sphingomyelin (SPM), 
whereas PC 32:0 is the most abundant [14,17]. Due to its chemical property, PC 
32:0 can be packed at high density onto the air-water interface thus lowering alveolar 
surface tension during inspiration [18,19]. Next to phospholipids, surfactant also 
contains neutral lipids like cholesterol (Chol) [14,17].  
The surfactant proteins are mainly composed of surfactant protein (SP)-A, SP-B, SP-
C, and SP-D. The large and hydrophilic SP-A and SP-D proteins belong to the family 
of collectins thereby opsonising pathogens and contributing to host-defence [20,21]. 
SP-B and SP-C proteins are small hydrophobic polypeptides packed into organelles 
called lamellar bodies (LBs), which produce and store pulmonary surfactant.  
LB biogenesis is a complex process with a number of intermediate steps. LBs derive 
from lysosomes and late endosomes by redistributing membrane phospholipids and 
fusion, resulting in multivesicular bodies (MVB) and composite bodies (CB) (Figure 1 
B) [21,22]. Moreover, surfactant lipids are likely transported by ABC transporters into 
LBs, especially by ATP-binding cassette subfamily A member 3 (ABCA3) [23]. 
Despite having an acidic pH and lysosomal features, LBs are secretory organelles 
and may therefore fuse with the plasma membrane of AT II cells [21]. After releasing 
the pulmonary surfactant into the alveolar space, the LBs are converted to tubular 
myelin, a defined lattice-like structure [19]. During inspiration, PL rapidly adsorb from 
tubular myelin to the air-water interface forming a functional surfactant film [19,24]. 
Interestingly, a proportion of 25-90% of pulmonary surfactant is recycled, suggesting 
a reinternalization into LBs followed by an eventual resecretion [25]. 
Recently, genetic disorders disrupting the surfactant metabolism have been 
recognized and identified in newborns and infants [26-30]. Despite its rarity, 
morbidity and mortality is considerable [3,31]. Sequence variations were found in 
genes involved in surfactant homeostasis, including SP-B gene (SFTPB), SP-C gene 
(SFTPC), and ABCA3 gene (ABCA3) [3]. Those inborn errors in newborns lead to 
severe RDS and of late onset ILD in children [14]. This entity represents one of the 
best molecularly characterized subgroup of ILD in childhood [32-34], while ABCA3 
gene variants are the most frequent cause [10,35].  
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Figure 1: Schematic representation of a pulmonary alveolus (A) and of lamellar body 
formation and pulmonary surfactant secretion in AT II cells (B)  
(A) adapted from [21]; (B) adapted from [36] 
1.3. The ABC transporter superfamily 
ATP-binding cassette (ABC) transporters are a large group of membrane proteins 
widely distributed among living organisms, such as bacteria, plants, and animals 
[37,38]. ABC proteins hydrolyze adenosine triphosphate (ATP), which provides the 
driving force for translocating molecules across membranes. These ATP-powered 
pumps cover a broad spectrum of substrates, including lipids, ions, xenobiotics, 
drugs, and hydrophobic compounds [39]. 
Functional ABC proteins contain two transmembrane domains (TMDs) and two 
nucleotide-binding domains (NBDs) [37]. Each TMD consists of six membrane-
spanning α-helices forming a cavity for substrate transport [40]. The NBDs, which 
bind and hydrolyze ATP, contain highly conserved domains: the Walker A and 
Walker B motifs found in all ABC transporters, and a unique signature motif located 
upstream of the Walker B domain [41,42]. 
Based on TMD folds and direction of transport relative to cytoplasm, four different 
ABC transporters were identified (Figure 2). Type I and type II importers together 
with ECF-transporters (type III importer) are exclusively expressed in prokaryotes, 
while exporters are found in both prokaryotes and eukaryotes [43]. Type I and II 
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importers depend on substance-binding proteins (SBP) or substance-binding 
domains (SBD), delivering molecules to the respective TMDs [44,45]. Type III 
importers possess specialized TMDs called S-components, which bind substrates 
with high affinity [46,47]. Exporters are involved in multidrug resistances, facilitating 
the export through cell membranes [48]. 
The human ABC superfamily comprises 49 ABC genes divided into seven 
subfamilies, termed A to G [49] (Table 1). Furthermore, defects in human ABC 
transporters were shown to cause genetic disorders [50,51] (Table 2).  
 
Figure 2: Overview of different ABC transporters  
Figure adapted from [43] 
SBP: Substrate-binding protein; TMD: Tansmembrane domain; NBD: Nucleotide-binding 
domain; CRD: C-terminal regulatory domain 
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Table 1: The superfamily of ABC transporters 
Subfamily 
name Aliases Gene 
Chromosome 
location Expression Function 
ABCA1 9q31.1 Ubiquitous Cholesterol efflux onto HDL 
ABCA2 9q34 Brain Drug resistance 
ABCA3 16p13.3 Lung Multidrug resistance 
ABCA4 1p22 Rod photoreceptors N-retinylidene-phosphatidylethanolamine (PE) efflux 
ABCA5 17q24.3 Muscle, heart, testes Urinary diagnostic marker for prostatic intraepithelial neoplasia (PIN) 
ABCA6 17q24.3 Liver Multidrug resistance 
ABCA7 19p13.3 Spleen, thymus Cholesterol efflux 
ABCA8 17q24 Ovary Transports certain lipophilic drugs 
ABCA9 17q24.2 Heart Might play a role in monocyte differentiation and macrophage lipid homeostasis 
ABCA10 17q24 Muscle, heart Cholesterol-responsive gene 
ABCA12 2q34 Stomach Has implications for prenatal diagnosis 
ABCA ABC1 
ABCA13 7p12.3 Low in all tissues Inherited disorder affecting the pancreas 
ABCB1 7q21.1 Adrenal, kidney, brain Multidrug resistance 
ABCB2 6p21.3 All cells Peptide transport 
ABCB3 6p21.3 All cells Peptide transport 
ABCB4 7q21.1 Liver Phosphatidylcholine (PC) transport 
ABCB5 7p15.3 Ubiquitous Melanogenesis 
ABCB6 2q36 Mitochondria Iron transport 
ABCB7 Xq12-q13 Mitochondria Fe/S cluster transport 
ABCB8 7q36 Mitochondria Intracellular peptide trafficking across membranes 
ABCB9 12q24 Heart, brain Located in lysosomes 
ABCB MDR 
ABCB10 1q42.13 Mitochondria Export of peptides derived from proteolysis of inner-membrane proteins 
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Subfamily 
name Aliases Gene 
Chromosome 
location Expression Function 
  ABCB11 2q24 Liver Bile salt transport 
ABCC1 16p13.1 Lung, testes, PBMC Drug resistance 
ABCC2 10q24 Liver Organic anion efflux 
ABCC3 17q22 Lung, intestine, liver Drug resistance 
ABCC4 13q32 Prostate Nucleoside transport 
ABCC5 3q27 Ubiquitous Nucleoside transport 
ABCC6 16p13.1 Kidney, liver Expressed primarily in liver and kidney 
ABCC7 7q31.2 Exocrine tissues Chloride ion channel (same as CFTR gene in cystic fibrosis) 
ABCC8 11p15.1 Pancreas Sulfonylurea receptor 
ABCC9 12p12.1 Heart, muscle Encodes the regulatory SUR2A subunit of the cardiac K+ (ATP) channel 
ABCC10 6p21.1 Low in all tissues Multidrug resistance 
ABCC11 16q12.1 Low in all tissues Drug resistance in breast cancer 
ABCC12 16q21.1 Low in all tissues Multidrug resistance 
ABCC MRP 
ABCC13 21q11.2 Unknown Encodes a polypeptide of unknown function 
ABCD1 Xq28 Peroxisomes Very-long chain fatty acid (VLCFA) transport 
ABCD2 12q11-q12 Peroxisomes Major modifier locus for clinical diversity in X-linked ALD 
ABCD3 1p22-p21 Peroxisomes Involved in import of fatty acids and/or fatty acyl-coenzyme As into the peroxisome 
ABCD ALD 
ABCD4 14q24 Peroxisomes May modify ALD phenotype 
ABCE OABP ABCE1 4q31 Ovary, testes, spleen Oligoadenylate-binding protein 
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Subfamily 
name Aliases Gene 
Chromosome 
location Expression Function 
ABCF1 6p21.33 Ubiquitous Susceptibility to autoimmune pancreatitis 
ABCF2 7q36 Ubiquitous Tumour suppression at metastatic sites and in endocrine pathway for breast cancer/drug resistance ABCF GGN20 
ABCF3 3q27.1 Ubiquitous Also present in promastigotes (one of five forms in the life cycle of trypanosomes) 
ABCG1 21q22.3 Ubiquitous Cholesterol transport 
ABCG2 4q22 Placenta, intestine Toxicant efflux, drug resistance 
ABCG4 11q23.3 Liver Found in macrophage, eye, brain and spleen 
ABCG5 2p21 Liver, intestine Sterol transport 
ABCG White 
ABCG8 2p21 Liver, intestine Sterol transport 
Table adapted from [49]and [52].  
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Table 2: Diseases caused by mutations in ABC genes 
Transporter 
name Disease 
ABCA1 Tangier disease; Familial hypoapoproteinemia 
ABCA4 Stargradt/fundus flavimaculatis; Retinitis pigmentosa; Cone-rod dystrophy; Age-related macular degeneration 
ABCB2 Immune deficiency 
ABCB3 Immune deficiency 
ABCB4 Progressive familial intrahepatic cholestasis-3 
ABCB7 X-linked sideroblastosis and anemia 
ABCB11 Progressive familial intrahepatic cholestasis-2 
ABCC2 Dubin-Johnson Syndrome 
ABCC6 Pseudoxanthoma elasticum 
ABCC7 Cystic fibrosis 
ABCD1 Adrenoleukodystrophy 
ABCG5 Sitosterolemia 
ABCG8 Sitosterolemia 
Table adapted from [50,53] and [51] 
1.3.1. The ABCA subfamily 
The ABCA subfamily comprises 12 transporters organised both as head-to-tail 
cluster on chromosome 17q24 and dispersed on six different chromosomes (Table 1, 
ABCA subfamily) [52,54]. Furthermore, ABCA transporters are widely expressed in 
different tissues and primarily involved in lipid trafficking (Table 1) [49,55].  
Several inherited diseases are caused by variations in the ABCA genes. Mutations in 
the ABCA1 gene are linked to Tangier disease, which is characterized by severe 
plasma deficiency or absence of high-density lipoprotein (HDL) and apolipoprotein A-
I [56]. The ABCA1 transporter plays a key role in the efflux of PL and free cholesterol 
(FC) from peripheral cells to lipid-poor apo A-I proteins [52,57].  
Another member of the ABCA family, the ABCA4 transporter, is mainly expressed in 
rod photoreceptors of the retina [58]. The ABCA4 transporter is thought to mediate 
the transport of modified PE across the cellular plasma membrane [59]. Variations in 
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the ABCA4 gene are associated with Stargardt disease, a retinal degeneration 
syndrome in childhood [58]. 
1.3.2. ABCA3 
The ABCA3 gene located on chromosome 16p13.3 encodes for a 1704 amino acid-
long protein and covers 80 kb of genomic DNA. ABCA3 is mainly expressed in the 
lungs, but also in liver, kidney, stomach, brain, and pancreas (Figure 3) [60,61]. 
Similar to SP-B and SP-C, ABCA3 expression is induced by thyroid transcription 
facor-1 (TTF-1) [62,63]. Usually, the ABCA3 protein is located to the limiting 
membrane of LBs, regulating LB biogenesis and pulmonary surfactant homeostasis 
[23,64,65]. Furthermore, the ABCA3 transporter is thought to exocytose PC and PG 
into the alveolar space [60,66].  
Previous studies showed a link of mutations in the ABCA3 gene with surfactant 
disorders in children, implicating a significant relevance to ILD [29,35,67]. Moreover, 
homozygous ABCA3-/- knock-out mice, which were unable to release surfactant into 
the alveolar space, soon died after birth. By contrast, heterozygous ABCA3-/+ knock-
out mice survived [68]. To date, more than 180 various ABCA3 mutations were 
found, resulting in trafficking, localization, and transport defects [60,69]. However, 
the precise mechanisms by which ABCA3 transporters act on surfactant metabolism 
remain unclear. 
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Figure 3: ABCA3 RNA expression in different tissues 
Adapted from [70] 
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2. Aims of the study 
The major aim of the study was to establish a system for characterizing and 
classifying different ABCA3 variations causing ILD. Therefore, we used a broad set 
of molecular tools to acquire knowledge about ABCA3 wild type protein. Based upon 
this, we analyzed ABCA3 mutations and compared them to the wild type protein. 
First, we explored cellular processing, trafficking, and intracellular localization of 
ABCA3 wild type protein and sequence variations in a reliable cellular model. Next, 
we analyzed LB morphogenesis in cells stably expressing ABCA3 wild type and 
protein variants. Furthermore, we investigated lipid transport function of ABCA3 wild 
type protein and different mutations. To proof its relevance, the in-vitro data were 
related to the respective ex-vivo data collected from patients carrying the same 
ABCA3 variations. 
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3. Results and Discussion 
ILD comprise a huge entity of diseases with mostly unknown cause. The inherited 
surfactant disorders as a subgroup of ILD are mainly caused by mutations in the 
ABCA3 gene. ABCA3 is a lipid transporter found in AT II cells, where it localizes to 
the limiting membrane of LBs, the intracellular production and storage organelles 
for pulmonary surfactant. To date, more than 180 different ABCA3 variants were 
found in patients suffering from ILD, but the molecular mechanisms of interacting 
with surfactant metabolism and homeostasis are still poorly understood. 
The central aims of the study were to explore wild type function of ABCA3, and to 
characterize and classify different ABCA3 variants causing ILD. Based on in-vitro 
assays and patient studies, we established a broad set of molecular tools, which 
allowed a detailed insight into ABCA3 function. 
3.1. Increased risk of interstitial lung diseases in children with a single 
R288K variant of ABCA3 
In this study we investigated the impact of the ABCA3 variant R288K on ILD. In 
our study cohort of 228 children suffering from ILD, we found nine patients 
harbouring the R288K mutation in a heterozygous state. The carrier frequency of 
R288K variant was enriched over that in the general Caucasian population [71]. 
Moreover, the patients had non-consanguineous parents and carried no sequence 
variations in SFTPB and SFTPC. All children with a single heterozygous R288K 
variant of ABCA3 developed neonatal respiratory distress and recurrent airway 
infections followed by chronic pediatric ILD. However, the patients did not exhibit 
characteristic features of complete ABCA3 deficiency. Two of nine patients 
displayed mild phenotypes of respiratory distress, suggesting additional factors 
involved in surfactant dysfunction. Moreover, correlation of prematurity in our 
patient cohort with single ABCA3 variations was proven and confirmed [72]. 
We provided evidence that the R288K variant reduces lipid transport activity of 
ABCA3 in the affected infants, proven by reduced levels of PC and PC 32:0 in 
bronchoalveolar lavage (BAL) fluids. In addition, decelerated detoxification 
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capacity for doxorubicin and reduced LB volume was shown in an appropriate cell 
model caused by functionally impaired ABCA3-R288K protein. 
Since expression of ABCA3 protein is a developmentally regulated process 
towards birth [61], prematurity has a pronounced effect resulting in elevated 
surfactant dysfunction. Previous studies demonstrated an increased susceptibility 
to lung injury in the presence of ABCA3 variations and respiratory tract infections, 
which was also a consistent feature in our patients [73,74].  
Taken together, we showed that the R288K variant in combination with prematurity 
or respiratory infections could lead to respiratory distress in newborns and ILD in 
children. 
3.2. Tools to explore ABCA3 mutations causing interstitial lung disease 
In the present study we used a set of molecular tools for characterization and 
classification different ABCA3 mutations according to their impact on ABCA3 
activity. The ABCA3 variant K1388N was exemplarily used to investigate 
molecular pathomechansims affecting pulmonary surfactant metabolism. 
Moreover, we aimed to correlate in-vitro and in-vivo findings. 
The homozygous K1388N variant was found in a patient suffering from severe 
respiratory distress, progressing to ILD with lethal outcome at the age of nine 
weeks. Furthermore, the K1388N mutation led to complete ABCA3 deficiency, 
which is incompatible with life [68]. 
Our study revealed that the K1388N variant was correctly localized to LBs in-vitro 
and was not retained in the endoplasmatic reticulum (ER). Moreover, ABCA3-
K1388N protein showed trafficking through ER and Golgi apparatus, which is 
consistent with ABCA3 wild type protein. We showed that K1388N mutation led to 
impaired cellular processing of ABCA3 protein. ABCA3 is normally processed from 
a 190 kDa form to a 150 kDa form [69,75]. The 190 kDa was clearly enriched in 
the sequence variant K1388N in-vitro. In addition, the replaced lysine to 
asparagine introduces a possible further N-glycosylation side on position K1388N; 
this may lead to decreased protein stability [76].  
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Furthermore, we showed an induction of LBs in our cell model stably expressing 
ABCA3 wild type protein. By contrast, expression of ABCA3-K1388N resulted in 
malformed LBs with decreased vesicle volume in-vitro and ex-vivo.   
Next, we assessed the impact of the K1388N variant on ABCA3 protein function 
by measuring lipid composition. PC and PC 32:0 content was both reduced in BAL 
of the patient and in our cell model stably expressing ABCA3-K1388N, which is in 
concordance with previous studies [62,77]. 
In summary, the K1388N variant was defined as a processing mutation with 
normal intracellular localization and a reduced lipid transporter activity for PC 32:0. 
The used molecular tools allow a detailed classification of different ABCA3 
mutations, thereby facilitating the screening for small molecule correctors in order 
to restore wild type function of ABCA3. 
3.3. Analysis of the proteolytic processing of ABCA3: identification of 
cleavage site and involved proteases 
Since the K1388N variation and other ABCA3 mutations lead to intracellular 
processing defects, we had a detailed look at the potential protease(s) cleaving 
ABCA3 from 190 kDa to 150 kDa form. Based on liquid chromatography–mass 
spectrometry (LC-MS/MS), we identified a proposed cleavage site of ABCA3 in 
proximity to Lys174, which was only detectable in the 190 kDa processing form. 
Analysis of a topological model of ABCA3 generated by TOPCONS indicated a 
localization of the potential cleavage site inside the vesicular lumen [78]. 
Moreover, previous studies revealed a N-terminally cleavage of ABCA3 protein in 
CD63-positive vesicles, which can be blocked by inhibition of vesicle acidification 
[79]. Furthermore, we showed that cleavage of ABCA3 proteins is blocked by E-
64, a cysteine protease inhibitor [79]. Therefore, the spectrum of proteases can be 
limited to lysosomal cysteine proteases acting at acidic pH.  
We narrowed down the list of proteases involved in ABCA3 cleavage using ALLM 
(N-Acetyl-Leu-Leu-Met-CHO), an inhibitor of calpains I and II, and cathepsins B 
and L [80]. We revealed an enrichment of the 190 kDa processing form compared 
to the 150 kDa form, which was diminished. Since the potential cleavage site of 
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ABCA3 protein is located in the vesicular lumen with acidic pH, calpains can be 
excluded.  
We next applied inhibitors specific for cathepsin B and cathepsin L. The cathepsin 
B inhibitor L-trans-expoxysuccinyl-Ile-Pro-OH propylamide methyl ester (CA-
074Me, [81]) led to an accumulation of the 190 kDa form, but had a weaker effect 
than ALLM, suggesting a lower activity of cathepsin B on ABCA3 protein cleavage. 
The inhibition of cathepsin L with N-1-napthalenesulfonyl-L-isoleucyl-L-
tryptophanal (NapSul-Ile-Trp-CHO, [82]) did not lead to an accumulation of the 190 
kDa form. Instead, both bands disappeared due to effects on cell viability. This is 
in concordance with previous reports [83]. 
These findings were verified by specific siRNA-mediated knockdown of cathepsin 
L and B expression [84], revealing an accumulation of the 190 kDa processing 
form. The effect was enhanced by combination of both cathepsin B and L 
knockdown. Moreover, synthesized peptides comprising residues 151-194 were 
cleaved by cathepsin L and to a lower content by cathepsin B after Lys174.  
Furthermore, we aimed to abolish the specific cleavage site for cathepsin L in the 
ABCA3 protein. Replacement of Leu173 and Lys174 by alanine residues resulted in 
an accumulation of the 190 kDa processing form of ABCA3. 
Taken together, we identified the specific cleavage site of ABCA3 protein at Lys174, 
which is processed by cathepsin L and to a lower level by cathepsin B. Since both 
processing forms seem to be necessary for normal function of ABCA3 protein, the 
identified proteases represent a potential target to therapeutically influence ABCA3 
activity in ABCA3-associated surfactant disorders. 
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ABSTRACT 
Rationale: The ABCA3 gene encodes a lipid transporter in type II pneumocytes critical for 
survival and normal respiratory function. The frequent ABCA3 variant R288K increases the 
risk for neonatal respiratory distress syndrome among term and late preterm neonates, but its 
role in children´s interstitial lung disease has not been studied in detail. 
Objectives: In a retrospective cohort study of 228 children with interstitial lung disease 
related to the alveolar surfactant system, the frequency of R288K was assessed and the 
phenotype of patients carrying a single R288K variant further characterized by clinical 
course, lung histology, computed tomography, and bronchoalveolar lavage 
phosphatidylcholine PC 32:0. Cell lines stably transfected with ABCA3-R288K were 
analysed for intracellular transcription, processing, and targeting of the protein. ABCA3 
function was assessed by detoxification assay of doxorubicin, and the induction and volume 
of lamellar bodies. 
Results: We found 9 children with interstitial lung disease carrying a heterozygous R288K 
variant, a frequency significantly higher than in the general Caucasian population. All 
identified patients had neonatal respiratory insufficiency, recovered, and developed chronic 
interstitial lung disease with intermittent exacerbations during early childhood. In-vitro 
analysis showed normal transcription, processing, and targeting of ABCA3-R288K, but 
impaired detoxification function and smaller lamellar bodies. 
Conclusions: We propose that the R288K variant can underlie interstitial lung disease in 
childhood due to reduced function of ABCA3, demonstrated by decelerated detoxification of 
doxorubicin, reduced PC 32:0 content, and decreased lamellar body volume. 
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INTRODUCTION 
Interstitial lung diseases (ILD) encompass a large number of diffuse parenchymal lung 
disorders involving the lung parenchyma and the alveolar interstitium [1]. The disease 
spectrum is much broader in childhood, as many diseases primarily manifest during infancy 
[2]. The surfactant dysfunction disorders are the best molecularly characterized subgroups of 
ILD [3–5], and among these, variants in the ATP-binding cassette sub-family A member 3 
(ABCA3) are the most frequent cause [6–8].  
The carrier frequency of heterozygous ABCA3 variants in the population predicts disease 
prevalence of 1 in ∼3100 European-descent and a total of ∼750 homozygous newborns 
annually in the United States [9]. This incidence is in the range of that for cystic fibrosis 
(about 1 in 2500 European-descent infants) [10]. However sick patients carrying ABCA3 
variants are not as frequently identified as could be expected based on these numbers. The 
main reason for this is the relatively large and thus costly analysis of the ABCA3 gene, which 
is assessed mainly in very severe, frequently lethal courses of respiratory distress syndrome in 
the mature neonate [11, 12]. Additional reasons include many not or only poorly defined 
ABCA3 variants with unclear pathogenic significance [9, 13]. Some variants lead to rare but 
well characterized chronic children’s interstitial lung disease with a firm histopathological 
pattern, including desquamative interstitial pneumonitis or non-specific interstitial 
pneumonitis [14, 15]. The ABCA3 variant R288K (c.863G>A) has been previously 
associated with pediatric respiratory disease [6] and a single copy was threefold to fourfold 
enriched among the European-descent infants with neonatal respiratory distress [9, 16, 17], 
although it is predicted to be benign and tolerated by the algorithms Polyphen and SIFT.  
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ABCA3 is a lipid transporter in alveolar type II cells, where it localizes to the outer 
membrane of lamellar bodies (LBs) which store surfactant. Variants in the ABCA3 gene can 
impair the intracellular localization, processing and transport activity of the ABCA3 protein. 
For instance, ABCA3 with the variants L101P, L982P, L1553P, Q1591P, and 
Ins1518fs/ter1519 was retained in the endoplasmatic reticulum, whereas N568D, G1221S, 
and L1580P mutant ABCA3 proteins were correctly localized in the LB limiting membrane, 
but showed decreased ATP hydrolysis activity compared to wild type protein [12]. ABCA3 
activity is also linked to LB biogenesis. Heterozygous ABCA3+/- knockout mice had fewer 
LB in their lungs [18]. Radiolabeled substrates, which were incorporated into newly 
synthesized disaturated phosphatidylcholine, phosphatidylglycerol, phosphatidylethanolamine 
and phosphatidylserine molecules, were lower in both LB and surfactant when compared to 
ABCA3+/+ mice [18]. Additionally, inherited ABCA3 variants caused a decrease of total 
phosphatidylcholine content in bronchoalveolar lavage of infants and raised surface tension 
compared to control group [19, 20]. Molecular species patterns of phosphatidylcholine, i.e. 
dipalmitoyl-phosphatidylcholine (PC 32:0), were also decreased in lavage of affected 
children [20]. 
In this study we investigated the hypothesis that the ABCA3 variant R288K may be 
permissive for children´s interstitial lung disease. Supportive of such a connection would be 
an increased frequency of this variant in a population of patients affected by ILD over the 
general population, ex-vivo evidence from these subjects for a certain functional impairment 
related to ABCA3, and in-vitro data from cells expressing this variant and proving 
functionally concordant cellular abnormalities. 
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METHODS 
Cohort 
Between 2003 and 2012, 377 infants and children were diagnosed in the program for rare 
lung diseases of the Kids-Lung Register as suffering from ILD related to the alveolar 
surfactant region on a clinical, radiological and sometimes histological basis [21]. 228 of 
these patients were sequenced for variants in the ABCA3 gene. In 62 patients possibly disease 
causing variants were identified and R288K was present in 11 cases. The latter patients were 
analysed in more detail (Supplemental tables 1, 2, 3). Two of these children (patients 10 and 
11 in Suppl. Table 1) had additional damaging homozygous ABCA3 variants very likely to 
cause ABCA3 insufficiency and determine their clinical course. These subjects were 
considered separately in further analysis as we intended to understand the role of 
heterozygous R288K alone or in association with non-damaging variants. As control cohorts 
for the sequence variant frequencies the Caucasian collections were used (National Heart, 
Lung, and Blood Institute Exome Variant Server (EVS)).  
 
Ethics Statement 
All parents or the guardians of the children gave their informed consent; an older youth 
assented. The retrospective analysis of the data was approved by the institutional review 
board (EK 026-06) of the University of Munich. Prospective collection and analysis of data 
was performed under (EK 257-10) and the FP7-305653 project chILD-EU (EK 111-13). 
 
Genetic analysis for ABCA3, SFTPC and SFTPB 
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Patients were investigated for variants in exons 4-33 of the ABCA3 gene (NM_001089), in 
exons 1-11 of the SFTPB gene (NM_000542), and in exons 1-5 of the SFTPC gene 
(NM_003018) [22]. Genomic DNA was amplified by PCR using the primers listed (Suppl. 
Tab. 4). Electrophoresis of sequenced products was performed on an Applied Biosystems 
3130xl Genetic Analyzer (Applied Biosystems, Darmstadt, Germany).  
 
Plasmids 
pT2/HB transposon vector was purchased from Addgene (Cambridge, United States, plasmid 
#26557). First, the puromycin resistance gene with corresponding PGK promoter elements 
was amplified from pLKO.1puro vector (purchased from Addgene, plasmid #8453) and 
cloned into the pT2/HB vector using EcoRI and HindIII restriction sites, yielding pT2/HB-
puro. Second, ABCA3 cDNA fused to a C-terminal HA-tag was amplified with corresponding 
CMV promoter elements from pcDNA4TO-ABCA3-HA vector and cloned into pT2/HB-puro 
using NheI and NotI restriction sites, yielding pT2/HB-puro-ABCA3-HA. The R288K point 
variant was introduced into pT2/HB-puro-ABCA3-HA using the Q5® site-directed 
mutagenesis kit (NEB, Massachusetts, United States) with following primers: R288K-for 5’-
GAGAAGGAAAAGAGGCTGAAGGAGTAC-3’ and R288K-rev 5’-
CTGCACGACAGCACGGGC-3’. pCMV(CAT)T7-SB100 transposase was ordered from 
Addgene (plasmid #34879). All resulting vector constructs were verified using Sanger 
sequencing. Sequence analysis and alignment was done using Clone Manager Suite (Version 
6.00). 
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Antibodies 
The following antibodies were used: rabbit anti-HA (Sigma, Taufkirchen, Germany), rat anti-
HA (Roche, Mannheim, Germany), mouse anti-CD63 (Abcam, Cambridge, United 
Kingdom), mouse anti-Calnexin (Novus Biologicals, Cambridge, United Kingdom), chicken 
horse radish peroxidase (HRP)-conjugated anti-β-Actin (Santa Cruz, Heidelberg, Germany), 
Alexa Fluor 488 goat anti-rabbit IgG and Alexa Fluor 555 goat anti-mouse IgG (Life 
Technologies, Darmstadt, Germany). 
 
Cell culture 
Human A549 and HEK293 cells were purchased from the German Collection of 
Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). Both cell lines were 
maintained in RPMI 1640 medium (Gibco, Darmstadt, Germany) supplemented with 10% 
fetal calf serum (FCS) (Sigma) at 37°C and 5% CO2. 
 
Generation of single clones stably expressing ABCA3-HA 
To evaluate the effect of the R288K point variant in-vivo, ABCA3-HA wildtype (WT) and 
mutated protein were stably transfected using the “Sleeping Beauty” transposon system into 
A549 cells and HEK293 cells, respectively. Therefore cells were seeded into 6-well plates 
and cotransfected with pCMV(CAT)T7-SB100 and pT2/HB-puro-ABCA3-HA WT or R288K 
respectively in the ratio of 2:5 using X-tremeGENE HP DNA transfection reagent (Roche). 
48 hours post transfection, selection of stable cells were started by addition of 1 µg/ml 
Puromycin (Sigma). Single cell clones were obtained by transferring single cells into the 
wells of a 96-well plate. 
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Immunofluorescence staining 
Stable A549 cells grown in 8-well slides (Ibidi, Martinsried, Germany) were washed twice 
with PBS (Sigma) and fixed with 4% paraformaldehyde (Sigma) for 20 min. After treating 
with 0.1 M glycine (Sigma) in PBS, cells were permeabilized with 0.1% TritonX 100 (Sigma) 
for 10 min. Unspecific binding sites were blocked with 3% BSA (Sigma) and 10% FCS in 
PBS for 30 minutes. Labelling with primary antibodies was carried out for 1 h at room 
temperature. Cells were washed three times with PBS and stained with the appropriate Alexa 
Fluor secondary antibodies. After washing three times with PBS, cells were stained with 0.1 
µg/ml DAPI (Sigma) for 10 minutes and washed with PBS. The cells were immediately 
covered with mounting medium (90% glycerine in PBS and 2% DABCO (Sigma)). Objects 
were viewed with an Olympus IX81/Fluoview FV1000 confocal laser scanning microscope 
and imaged with the Olympus Fluoview version 4.2 software. 
 
Real-time PCR  
Total RNA was collected from cells grown for 48h in 6-well plates using the High-Pure RNA 
Isolation Kit (Roche) according to the manufacturer’s instructions. RNA concentrations were 
determined with a NanoDrop spectrophotometer (Thermo Scientific, Darmstadt, Germany). 
One microgram of total RNA was transcribed into cDNA with the Tetro cDNA Synthesis Kit 
(Bioline, Luckenwalde, Germany). Real-time PCR was carried out on a 7900HT Fast Real-
Time PCR System (Bioline) using SYBR green (Life Technologies) and following primers: 
ABCA3-for 5’-CATGGTCAGCACCTTCTTCA-3’, ABACA3-rev 5’-
TTCTGGCTCAGAGTCATCCA-3’, HPRT-for 5’-GCTGACCTGCTGGATTAC-3’ HPRT-rev 
5’-TGCGACCTTGACCATCTT. Relative changes in gene expression caused by ABCA3-WT 
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or R288K variant were calculated using the 2-ΔΔCT method with hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) as housekeeper. 
 
Immunoblotting 
Cells were seeded in 6-well plates for 48h and then rinsed with PBS once and subsequently 
trypsinized and again washed with PBS. After that, cells were lysed with 
radioimmunoprecipitation assay (RIPA) buffer containing 0.15 M sodium chloride, 1% 
Triton-X 100, 0.5% sodium deoxycholate, 0.1% sodium dodecylsulfate, 5 mM ethylene 
diamine tetraacetic acid (EDTA) and 50 mM Tris pH 8 (Sigma). RIPA buffer was 
accomplished by complete protease inhibitor (Roche). The lysate was centrifuged for 30 min 
at 1000 x g and 4°C. The Protein concentration of the post-nuclear supernatant (i.e. whole-
cell lysate) was determined with the Pierce BCA protein assay using bovine serum albumin 
(BSA) as the protein standard. Totally, 20 µg of cell lysates in 4xLDS buffer (Invitrogen, 
Darmstadt, Germany) were loaded onto NuPage Mini Tris-Acetate gels (Invitrogen). 
Following gel electrophoresis, proteins were blotted to polyvinylidene fluoride membranes 
(Millipore, Darmstadt, Germany). After transfer, membranes were blocked with 5% skim 
milk in TBS-T (Sigma). Membranes were incubated over night with primary antibodies in 
blocking solution. After washing the membranes three times with TBS-T, HRP-conjugated 
secondary antibodies were applied 1 h at room temperature. Detection was performed using 
ECL reagent (GE Healthcare, Munich, Germany). 
 
Viability assay 
Cell viability was assessed by determining cleavage of 2,3-bis (2-methoxy-4-nitro-
sulfophenyl)-2H-tetrazolium-5-carboxyanilide (XTT, Sigma) in the presence of phenazine 
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methosulfate. For XTT assay, cells were seeded in 96-well plates in RPMI medium 
containing 10% FCS and no phenol red. After different points of time, absorbance was 
measured at 490 nm and 650 nm using a spectrophotometer. 
 
Cytotoxicity assay 
Triplicates of A549 cells stably transfected with ABCA3-WT and ABCA3-R288K and cells 
transfected with mock control were seeded into 6-well plates. After an incubation time of 
96h, cell supernatants were harvested and the amount of the lactate dehydrogenase (LDH) 
enzyme was quantified colorimetrically at 490 nm using the CytoTox 96® Non-Radioactive 
Cytotoxicity Assay (Promega, Mannheim, Germany) according to the manufacturer’s 
instructions. The resulting optical densities were referred to numbers of cells counted with the 
Cellometer Auto T4 Cell Viability Counter (Nexcelom, Bramsche, Germany). 
 
Lipid analyses of human bronchoalveolar lavages 
After protein level determination, lipids of bronchoalveolar lavages (BALs) obtained from the 
patients were analysed by ESI-MS/MS in positive ion mode as described [20]. 
Doxorubicin assay 
For doxorubicin assay HEK293 cells stably expressing ABCA3 wild type protein or R288K 
variant were seeded as octuplicate in 96-well plates at a density of 1 x 105 cells per well. After 
attaching to 96-well plate HEK293 cells were treated with different concentrations of 
doxorubicin for 3h. Cells were washed subsequently with PBS and incubated for further 24h 
in RPMI medium containing 10 % FCS and no phenol red under normal conditions. Viability 
was measured with XTT assay (as previously described). 
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Electron microscopy 
Cells were fixed in 150 mM HEPES, pH 7.35, containing 1.5 % formaldehyde and 1.5 % 
glutaraldehyde (Sigma) at room temperature for 30 min and then at 4°C overnight. After 
dehydration in acetone, cells were embedded in EPON. 50 nm sections were stained with 4 % 
uranyl acetate and lead citrate and observed in a Morgagni TEM (FEI). Images were taken 
with a 2 K side mounted Veleta CCD camera. 
 
Calculation of vesicle volume 
A549 cells containing either ABCA3 wild type or R288K protein variant were seeded in 8-
well slides (Ibidi). After an incubation time of 48h, cells were fixed as described above and 
immunostained against HA-tag. Cells were imaged with the confocal laser scanning 
microscope. Diameter of each ABCA3-HA containing vesicle was determined with ImageJ 
software tool. Vesicle volume was calculated with formula:     . 60 different 
ABCA3-HA containing vesicles were randomly chosen from three distinct experiments, thus 
analysing 20 vesicles per condition and experiment. 
 
Statistical analyses 
Dependency on gestational age of the different ABCA3 variants was analysed using Fisher’s 
exact test. Comparisons of two groups were done using student’s t-test. Comparisons of 
multiple groups were done using one-way repeated measure ANOVAs with Tuckey’s post 
hoc test. Doxorubicin assay, phospholipid (PL) classes and phosphatidylcholine (PC) species 
were analyzed using two-way repeated measure ANOVAs with Sidak’s post hoc test. Results 
were presented as mean ± SEM of a minimum of three different experiments. P-values < 0.05 
were considered to be statistically significant. All tests were performed using Graph-Pad 
Prism 6.0 (GraphPad Software). 
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RESULTS 
Clinical characterization of children with interstitial lung disease and R288K 
In our cohort of 228 children with ILD and ABCA3 sequenced, we identified 11 subjects as 
carriers of R288K. This frequency of R288K was clearly enriched over that in the general 
Caucasian population (71 R288K in 4229 Caucasian subjects of the Exom variant server 
(National Heart, Lung, and Blood Institute Exome Variant Server (EVS)) (P=0.0014)). We 
next analysed the dependency on gestational age of the different ABCA3 variants identified. 
Whereas all the other possibly disease causing ABCA3 variants were evenly distributed 
among mature and immature infants, R288K was found more frequently in premature infants 
(Table 1). 
All our patients carrying a single heterozygous R288K variant were Caucasians, had non-
consanguineous parents and did not carry known disease-causing genetic variants in SFTPC 
and SFTPB (Suppl. Table 1). In all children, the initial manifestation of lung disease was 
during the neonatal period, only 5 were premature infants (median gestational age 30 weeks, 
range 27 to 32). 6 children were mechanically ventilated; most recovered and had chronic or 
intermittent episodes with respiratory symptoms during infancy and childhood. Those old 
enough to perform lung function tests had restrictive lung disease (Suppl. Table 2). The CT 
pattern was consistent with ILD in 6 of the 9 children. In 2 where no CT scan was available 
histology documented ILD. Six of the 9 children had lung biopsies, always showing ILD 
alone or in combination with emphysematous areas (Suppl. Table 3). 
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No evidence for impaired ABCA3 transport activity in children with chronic ILD and 
heterozygous for R288K 
Initially, we excluded severe ABCA3 deficiency as the molecular cause of the diseases by 
excluding complete ABCA3 deficiency and demonstrating evidence for some ABCA3 
function (Table 2). The subjects had regular ABCA3 histopathologic staining (available in 4 
subjects), had normally formed lamellar bodies (available in 3 subjects) or had a dipalmitoyl-
phosphatidylcholine (PC 32:0) content in bronchoalveolar lavage (in 6 subjects available) that 
was on average a little higher than typically found in infants with ABCA3 deficiency, but 
significant lower than in healthy children (Figure 1). In 3 other subjects, no such 
investigations were done due to mild and improving course.  
It was of interest that all patients heterozygous for R288K presented to us, as infants or 
children, rather than as neonates, with an unusual course of ILD, and which, their treating 
physicians could not explain by prematurity or perinatal lung injury. All surviving children 
improved, but their ILD was not cured at follow up. Despite broad clinical investigations, no 
other causes of their ILD could be identified.  
To summarize, these children with chronic ILD had enrichment of the R288K variant in 
ABCA3 and somewhat reduced dipalmitoyl-phosphatidylcholine in the alveolar space, i.e. 
strong epidemiologic and biochemical evidence for an involvement of ABCA3 in their 
pathogenesis. Although the R288K variant was predicted not to be detrimental to protein 
function by SIFT and Polyphen, our data nonetheless suggest impairment of ABCA3 function 
due to the presence of this particular variant. Therefore, we performed detailed studies on the 
cellular effects of the R288K variant. 
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Transcription, intracellular processing, and cellular targeting of R288K in ABCA3-
transfected lung cells 
Stable transfection of A549 cells with DNA coding for ABCA3-WT or ABCA3-R288K 
induced ABCA3-mRNA transcription of 200-fold compared to mock transfected cells 
(Supplemental Figure 1A). Intracellular processing as assessed by Western immunoblotting 
did not differ between ABCA3-WT and ABCA3-R288K. Both proteins were present as the 
190 and 170 kDa processing forms (Supplemental Figure 1B) and their intensity ratios did not 
differ (Supplemental Figure 1C). Cell growth and proliferation were unaffected in 
comparison to mock controls (Supplemental Figure 1D, 1E). Intracellular localization was 
investigated by immunofluorescence staining and revealed normal colocalization of both, the 
wild type and the R288K mutated ABCA3 protein with CD63, a marker for late endosomes 
and lamellar bodies (Supplemental Figure 1F). Obvious protein misfolding was ruled out by 
lack of colocalization with the ER-resident chaperone calnexin (Supplemental Figure 1G). 
These findings were confirmed independently in HEK293 cells. Whereas there was no 
difference in protein expression, mRNA expression differed between ABCA3-WT and 
ABCA3-R288K expressing cells (Supplemental figure 2). 
Impaired ABCA3-dependent doxorubicin detoxification in R288K variants 
ABCA3 transport activity was analysed in HEK293 cells stably transfected with ABCA3-WT 
or ABCA3-R288K by means of their ability to detoxify doxorubicin (Supplemental Figure 2). 
High activity of the transporter, i.e. overexpression of ABCA3 protein in childhood acute 
myeloic leukaemia patients, induced resistance against doxorubicin [23]. HEK293 cells stably 
expressing R288K mutated ABCA3 protein had a diminished viability compared to cells 
expressing WT protein when treated with 5,10 or 20 µM of doxorubicin respectively (Figure 
2A). In concordance, the morphology of the cells expressing ABCA3-R288K was altered to a 
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round-shaped appearance compared to ABCA3-WT expressing cells (Figure 2B; 10 µM 
Doxo). These results point to a reduced ABCA3 transport activity as a result of the R288K 
variant. 
Lamellar bodies of ABCA3 with the R288K variant  
Electron microscopy of A549 cells stably expressing ABCA3-WT or R288K mutated protein 
revealed an induction of lamellar body (LB)-like structures in A549 cells (Figures 3A, 3B). 
LB-like structures of both cell lines showed well-formed organelles containing concentric 
membranes arranged in parallel. Volumes of LB-like structures in cells expressing ABCA3-
R288K were quantitatively compared to cells expressing ABCA3-WT protein. Using 
immunofluorescence staining of A549 cells stably expressing ABCA3-R288K, smaller 
ABCA3-positive vesicles were found compared to cells expressing ABCA3-WT protein 
(Figure 4). 
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DISCUSSION 
 In this study we present a cohort of children with chronic ILD characterized by their 
carriage of a single R288K variant of ABCA3. All children suffered from a mainly restrictive 
lung disease with the typical histological and chest CT imaging pattern of chronic pediatric 
ILD. However, they did not exhibit the generic features of complete ABCA3 deficiency. We 
present evidence that the presence of the R288K variant interferes with ABCA3’s transport 
activity. Therefore, we propose that the development and long term persistence of chronic 
ILD in our cohort was due to the presence of a single R288K variant of ABCA3 and not a 
result of their neonatal history of respiratory distress following either term or preterm birth.  
 Manifestation of ABCA3 deficiency due to homozygous or compound heterozygous 
variants causes severe respiratory distress in mature infants, frequently leading to early death 
[11, 12] or chronic ILD in a small number of older children and young adults [14, 15]. In this 
study, we characterize subjects carrying the R288K variant on a single allele and suffering 
from a characteristic chronic pediatric ILD phenotype. Whereas the individual course of their 
lung disease was quite variable, all patients had a characteristic diffuse parenchymal lung 
disease. Histology of lung biopsies demonstrated ILD present with almost the entire spectrum 
of histologic patterns known for these conditions, including pulmonary alveolar proteinosis 
(PAP), non-specific interstitial pneumonitis (NSIP), desquamative interstitial pneumonitis 
(DIP), chronic pneumonitis of infancy (CPI), interstitial emphysema, dystelectasis and 
eosinophilia, often in combination. Such heterogeneity is not unusual, even in the presence of 
the same disease causing variants [2, 4, 21], and likely represents the morphologic response 
of lung parenchyma to variable injuries in different individuals.  
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 Our data suggest that heterozygous R288K variants in ABCA3 are not strong enough 
determinants permitting the manifestation of ILD in the absence of additional factors. This is 
supported by the fact that only two out of nine parents carrying the variant had some, but not 
severe respiratory symptoms. However, the precise nature of their conditions was not 
investigated to great detail. In our patients, neonatal respiratory distress was a consistent 
feature, together with injury from recurrent airway infections. The strong interaction of single 
ABCA3 variants and prematurity was previously demonstrated [17] and confirmed here. 
Other modifying factors may be present like cis-acting elements, introns or non-translated 
regions within the ABCA3 gene, which were not covered by our sequencing strategy [24]. 
Whereas variants in SFTPC or SFTPB were excluded, variants in other genes not directly 
related to ABCA3 expression, epigenetic regulation, and additional environmental or 
developmental factors are also conceivable. Furthermore, previous studies showed that some 
ABCA3 variants had a mild cellular effect, associated with increased inflammation [25]. 
Lower levels of phosphatidylcholine and dipalmitoyl-phosphatidylcholine in the 
alveolar space of the infants are likely to be a result of functional impairment of ABCA3-
R288K. The other phospholipid species (lyso-phosphatidylcholine, phosphatidylglycerol, 
sphingomyelin, phosphatidylethanolamine, phosphatidylserine) were not different. 
Additionally, a reduced capacity for detoxification of doxorubicin and a smaller volume of 
ABCA3-positive vesicles provide in-vitro evidence for reduced ABCA3 transport function 
due to the presence of the R288K variant. Taken together these data point to a causative role 
of the R288K variant. Although the functional impairment of ABCA3-R288K is likely too 
small to induce lung disease on its own, when acting in combination with significant 
respiratory stress at birth or later in life during respiratory tract infections, its effects will 
become amplified and will cause notable clinical symptoms. 
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As there is a strong developmental dependency of ABCA3 expression with an 
increase towards birth [26], an increased vulnerability in premature infants is expected. The 
strong association of the R288K variant with respiratory distress obviously results from a 
partially defective surfactant lipid transport, which will have a more pronounced effect the 
more immature the baby.  
Mice carrying ABCA3 knockout on a single allele show an increased susceptibility to 
injury [27]. Similarly, single point variants in the ABCA3 gene can reduce the expression of 
mature protein, presumably by increasing ER-associated degradation of misfolded protein 
[28]. Beyond the neonatal period, infants carrying a single R288K variant of ABCA3 may be 
more vulnerable to lung injury affecting the alveolar space, resulting in an increased risk of 
chronic pediatric ILD involving surfactant dysfunction. Among the most likely mechanisms 
triggering ILD in our patients were the frequently observed viral and other respiratory tract 
infections, which put an enormous burden on the ABCA3-dependent lung surfactant system. 
As demonstrated previously and in agreement with our ex-vivo measurements, infection with 
respiratory syncytial virus strongly impaired the expression of alveolar type 2 cell 
differentiation marker SP-C and other key epithelial cell proteins in the presence of ABCA3 
varints. Simultaneously, a mesenchymal phenotype was acquired, indicating development of 
pulmonary fibrosis [29].  
Our observations imply that the presence of a single mutated allele is permissive to 
cause symptoms in conjunction with common and usually well-tolerated burdens of the 
respiratory system. This is in concordance with findings in individuals with single allele 
variants in another ABC transporter, i.e. ABCA7 also called cystic fibrosis transmembrane 
regulator (CFTR). The expression of single alleles increases the risk for bronchiectasis [30, 
31] and rhinosinusitis [32], as well as extra pulmonary manifestations of cystic fibrosis like 
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pancreatitis [33, 34] or azoosermia [35]. In the case of ABCA3-R288K, it remains to be 
elucidated whether the effects of the variants can be explained by haploinsufficiency alone or 
if the variant exerts a dominant-negative effect. 
Whereas a major strength of our study is the detailed cellular analysis of the R288K 
variant, identifying mechanisms by which it may exert its disadvantageous effects, there are 
some weaknesses in our study, including its retrospective design resulting in variable follow 
up, a relatively low number of cases due to the rarity of pediatric ILD, and the fact that 
biopsies were obtained in many but not all cases. In addition the cellular model is not perfect 
as clonal differences might account in part for the results; the transfection is homozygous 
since either ABCA3-WT or R288K variant were introduced and, although we used two 
different cell lines yielding similar results, these are still different from primary type II cells. 
On the other hand, this is a third and independent cohort demonstrating some pathogenic 
potential of R288K, showing for the first time a role in pediatric ILD, and providing detailed 
cell biological analysis.  
 Taken together, we show that the presence of the ABCA3-R288K variant on a single 
allele, when acting together with aggravating external stressors like prematurity or recurrent 
respiratory infections, can cause respiratory insufficiency and ILD. We also demonstrate that 
in spite of R288K having been predicted to be neutral by in-silico prediction algorithms, this 
particular variant indeed may cause functional impairment of ABCA3 leading to clinically 
relevant consequences. This finding also highlights the notion that results from prediction 
algorithms for variants identified during analysis of next generation sequencing data need to 
be backed by clinical and experimental data. 
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LEGENDS TO THE FIGURES 
 
Fig 1: Levels of phosphatidylcholine and dipalmitoyl-phosphatidylcholine in 
bronchoalveolar lavage fluid of infants heterozygous for R288K in ABCA3. 
A. Phosphatidylcholine of patients carrying heterozygote R288K variant (n=4) compared to 
healthy control group (n=11). Data are shown in % of all analyzed PL classes measured in 
BAL. B. Dipalmitoyl-phosphatidylcholine amounts of healthy patients (n=11) and patients 
with R288K variant (n=4) measured in BAL. Data are shown in % of total PC. All results 
were expressed as mean ± SEM. *p < 0.05; ***p < 0.001 
 
Fig 2: Induction of cellular multidrug resistance in-vitro by ABCA3. A. Effects of soluble 
doxorubicin on viability of HEK293 cells stably expressing ABCA3-WT or ABCA3-R288K 
protein. Different concentrations of doxorubicin were used and viability was measured with 
XTT assay. Values are displayed as means ± SEM of HEK293 cells stably expressing either 
ABCA3 wild type protein (solid line) or R288K mutated ABCA3 protein (dashed line). *P < 
0.05; ****P < 0.0001. B. Light microscopy of HEK293 cells stably expressing ABCA3-WT 
and ABCA3-R288K protein respectively. Additionally cells were treated with 10µM 
doxorubicin for 3h and displayed after 24h of growth in RPMI medium supplemented with 
10% FCS under normal conditions. 
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Fig. 3: Transmission electron microscopy. Electron Microscopy of A549 cells expressing 
ABCA3-WT (A) or ABCA3-R288K (B). Several lamellar bodies are visible in the overviews. 
These exhibit concentric lamellae, as distinguishable in the higher magnifications (insets). 
Scale bars are 1 µm for overviews and 0.5 µm for insets. 
 
Fig. 4: Determination of vesicle volumes in A549 cells with ABCA3-WT or ABCA3-
R288L protein. A. Immunofluorescence staining of HA-tagged ABCA3 vesicles imaged 
with a confocal microscope. Shown is either ABCA3-WT (left) or ABCA3-R288K 
containing vesicles (right). B. Volumes of ABCA3 containing vesicles harbouring either 
ABCA3-WT or ABCA3-R288K were calculated on the basis of vesicle diameters determined 
with ImageJ software tool. ***P<0.001 
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T
A
B
L
E
S 
Table 1: Frequencies of A
B
C
A
3 variants am
ong 228 neonates and infants (m
ean gestational age 35.4 w
eeks) sequenced for A
B
C
A
3 variants and 
interstitial lung disease.  
 G
estational age (w
ks) 
< 37 
> 37 
 
M
ean gestational age (w
ks) 
31.6 
31.3 
39.4 
39.4 
 
A
B
C
A
3 variant present 
Y
es 
N
o 
Y
es 
N
o 
P# 
A
ny variants 
15 
48 
47 
118 
0.5106 
R
288K
 
6 
8 
5 
43 
0.0012 
R
288K
 w
ithout other disease causing A
B
C
A
3 variant (n=2) 
6 
8 
3 
43 
0.0001 
 # Fisher's exact test 
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 Table 2: Ex-vivo evidence for functionality of A
B
C
A
3 transport activity 
 Patient 
C
ode 
Im
m
unohistologic 
staining for A
B
C
A
3 
Electron-
m
icroscopy 
D
ipalm
itoyl-phosphatidylcholine (PC
 
32:0) (%
 total PC
) in B
A
L 
O
verall evidence for A
B
C
A
3 transport 
activity 
 
Expected 
norm
al 
result #: 
Type 2 cells w
ith 
granular ring like 
structures 
C
oncentric 
lam
ellar 
45.8 ± 3.6
## 
 
1 
199 
N
.a. 
Y
es, norm
al 
40.8 
Y
es 
2 
652 
N
.a. 
N
.a. 
40.7 
Y
es 
3 
1300 
Y
es, norm
al 
Y
es, norm
al 
41.1 
Y
es 
4 
1468 
Y
es, norm
al 
N
.a. 
42.1
### 
Y
es 
5 
1479 
Y
es, norm
al 
N
.a. 
23.5 
Y
es, m
arginal 
6 
1601 
N
.a. 
N
.a. 
n.a. 
Y
es, no investigations as m
ild course 
7 
2253 
Y
es, norm
al 
Y
es, norm
al 
30.6
### 
Y
es 
8 
2405 
N
.a. 
N
.a. 
n.a. 
Y
es, no investigations as m
ild course 
9 
2741 
N
.a. 
N
.a. 
n.a. 
Y
es, no investigations as m
ild course 
#G
riese, K
ierm
eier et al 2015; ##D
ipalm
itoyl-phosphatidylcholine (PC
 32:0) w
as 12.7 ± 4.2 %
 of total PC
 in 4 subjects w
ith severe neonatal 
disease causing A
B
C
A
3 variants; ###Lung tissue. N
.a. = N
ot available 
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Supplem
ental M
aterial 
Supplem
ental table 1. G
enetic data of the patients 
 Patient 
Sex 
Ethnics 
Fam
ily history 
A
B
C
A
3 sequence variant 
SFTPB
 
SFTPC
 
1 
Fem
ale 
C
aucasian 
M
other 33y, I grav, I para 
R
288K
 heterozygous 
nl 
nl 
2 
Fem
ale 
C
aucasian 
M
other IV
 grav, III para 
R
288K
 heterozygous 
nl 
nl 
3 
M
ale 
C
aucasian (f)  
Pacific Islander 
Polynesian (m
),  
M
other, brother: bronchial asthm
a,  
Father: lung problem
s 
R
288K
 heterozygous 
nl 
nl 
4 
M
ale 
C
aucasian 
G
em
inus I, 22 gest w
k death of sibling 
R
288K
 heterozygous 
nl 
nl 
5 
Fem
ale 
C
aucasian 
Parental sm
oking 
R
288K
 heterozygous 
+/- Pos -
384 
nl 
6 
M
ale 
C
aucasian 
M
other healthy, no lung sym
ptom
s 
R
288K
 heterozygous 
nl 
C
C
 to G
T sub- 
stitution at -92 to -91  
to A
TG
 start codon,  
heterozygous 
7 
M
ale 
C
aucasian 
Tw
in died short after birth due to lung 
failure 
R
288K
 heterozygous, 
 P766S  heterozygous, (trans) 
nl 
nl 
8 
Fem
ale 
C
aucasian 
M
other: hem
ithyroidectom
y; father: 
bronchial  
asthm
a, suspected ILD
, no biopsy taken 
R
288K
 heterozygous,  
S693L heterozygous (both cis) 
nl 
nl 
9 
Fem
ale 
C
aucasian 
N
one 
R
288K
 heterozygous 
n.d. 
nl 
10 
Fem
ale 
C
aucasian 
N
one 
R
43L/R
288K
+c4751 
delT (fram
eshift) com
- 
pound heterozygous (trans) 
nl 
nl 
11 
M
ale 
A
frican 
N
one 
Q
215K
 hom
ozygous,  
R
288K
 hom
ozygous 
nl 
nl 
 nl = norm
al, n.d. = not done 
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Supplem
ental table 2. N
eonatal history, lung function and C
T scan of the children w
ith chronic interstitial lung disease and R
288K
 in A
B
C
A
3 
Pati
ent 
G
est
. Age 
O
xygen 
neo. 
Period 
M
ech. 
V
entilation 
neo. Period 
O
nset 
lung di-
sease (y) 
C
ourse lung disease 
Lung function 
C
T scan 
1 
39 
Y
es 
Y
es 
0.1 
6 w
ks: tachydyspnea, cyanosis, 
w
heezing; 
N
.a. 
4 m
onths: bilateral interstitial diffuse 
infiltration 
2 
36 
Y
es 
Y
es 
0.0 
Postpartal tachypnea; 6 m
on R
D
S 
due to bronchopneum
onia; 8 m
on 
R
D
S due to U
TI; bronchial 
hyperreactivity 
7y: FEV
1 54%
, FV
C
 56%
 
13 m
on: ground glass attenuation; 
6y:bronchopneum
onia, hilar 
lym
phadenopathy 
3 
32 
Y
es 
N
o 
0.1 
R
D
S, persistent need of oxygen 
N
.a. 
Interstitial changes, thickened septa, air 
trapping, em
physem
a 
4 
27 
Y
es 
Y
es 
0.0 
R
D
S 
N
.a. 
N
.d. 
5 
30 
Y
es 
Y
es 
0.0;  
4.3 
R
D
S 3d ventilated, 8 d C
PA
P, 4.25y 
dyspnea, cyanosis, coughing attacks, 
tachypnea, w
heezing; 8y rec. 
respir.infections 
8y: no desaturation under 
physical perform
ance 
4.5y: honey com
b pattern bilateral, 
ground glass attenuation; 7y: 
bronchiectasis 
6 
30 
Y
es 
N
o 
0.0 
C
ongenital lobar em
physem
a and 
interstitial lung disease 
11y: FEV
1 58%
, FV
C
 52%
 
3 m
onths: em
physem
a and m
osaic pattern 
in under-developed lung. 7 y: basal 
thickened and rarefied interlobar septa; 
m
osaic perfusion; em
physem
a 
7 
29 
Y
es 
Y
es 
0.0 
R
D
S 26d ventilated, B
PD
, 
pulm
onary hypertension 
N
.a. 
N
.a. 
8 
37 
Y
es 
Y
es 
0.0 
0.2y: oxygen need, deteriorations of 
saturation; 1.8y: obstructive 
episodes 
N
.a. 
1 m
on: dim
inished ventilation, ground-
glass attenuation bilateral 
9 
37 
N
o 
N
o 
0.0 
Tachydypnea since birth, 2.0 y 
recurrent broncho-pulm
onary 
infections  
1
st lung function: LC
I 9.5, 
central obstruction, lung 
com
pliance decreased 
8.7m
l/kPa/kg 
2
nd lung function , at 7m
o LC
I 
norm
al, com
pliance im
proved 
10 m
l/kPa/kg 
1
st C
T: M
osaic pattern, ventilation 
inhom
ogeneities, no tracheobronchial 
m
alacia, ectasy of LA
D
-coronary artery 
2
nd C
T, at 7 m
o, norm
al lung parenchym
a, 
no ventilation inhom
ogeneity, constant 
ectatic LM
, LA
D
, R
C
A
 after K
aw
asaki's 
disease 
10 
42 
Y
es 
Y
es 
0.0 
Postpartal tachydyspnea, cyanosis 
N
.a. 
N
.a. 
  
39 
11 
40 
N
o 
N
o 
0.0 
N
o inform
ation 
N
.a. 
N
.a. 
  B
PD
 = B
ronchopulm
onary dysplasia; C
PA
P = continuous positive airw
ay pressure; FEV
1 = forced expiratory volum
e in 1 second; FV
C
 = forced 
vital capacity; LC
I = lung clearance index; R
D
S = respiratory distress syndrom
e. N
.a. = not available 
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Supplem
ental table 3.   Lung biopsy and other diagnosis, treatm
ent, outcom
e of children w
ith chronic interstitial lung disease and R
288K
 in 
A
B
C
A
3 
 
Patient 
Lung 
biopsy 
Final pulm
onary and additional diagnosis 
Treatm
ent 
Follow
 up if 
alive or age of 
death (y) 
Long term
 
outcom
e 
1 
y 
ILD
 w
ith PA
P pattern, m
ild lym
phocytic 
infiltration 
Prednisolone 
0.4 
dead 
2 
n 
ILD
 w
ith ground glass attenuation and 
septal thickening  
A
rnold-C
hiari m
alform
ation Typ II; 
recurrent airw
ay infections 
Prednisolone, antibiotics, long term
 oxygen 
(until age 7, now
) 
7.0 
sick-better 
3 
y 
ILD
, W
ilson M
ikity Syndrom
e 
D
iuretics, inhalation, oxygen 
3.9 
sick-better 
4 
y 
ILD
 / B
PD
, interstitial em
physem
a, 
dystelectasis, bronchiolitis 
Surfactant 
0.1 
dead 
5 
y 
ILD
 w
ith N
SIP, D
IP pattern; eosinophilia 
H
ydroxychloroquine, azathioprine until 6.5y; 
steroid boosts until 8y, azithrom
ycin 
8.0 
sick-better 
6 
y 
Thickened and rarefied interlobar septa; 
m
osaic perfusion; em
physem
a; 
dysalbum
inem
ic hyperthyroxinem
ia, short 
stature 
Inhaled steroids, diuretics, system
ic steroids, 
theophylline; som
atotropin 
9.0 
sick-better 
7 
y 
ILD
 w
ith C
PI, N
SIP, and D
IP pattern 
O
xygen, corticosteroids 
0.5 
dead 
8 
n 
ILD
, chronic respiratory sym
ptom
s; has 
healthy tw
in 
Surfactant, dexam
ethasone; 1.8y: m
ontelukast, 
salbutam
ol 
3.0 
sick-better 
9 
n 
ILD
 w
ith ground glass attenuation, 
K
aw
asaki syndrom
e, aneurysm
 LC
X
 
O
xygen, aspirin 
4.0 
sick-better 
10 
y 
ILD
 previously published (case 3)# 
O
xygen, m
echanical ventilation 
0.2 
dead 
11 
y 
ILD
 previously published (case 5)# 
O
xygen, m
echanical ventilation 
0.3 
dead 
 B
PD
 = B
ronchopulm
onary dysplasia; C
PI = chronic pneum
onitis of infancy; D
IP = desquam
ative interstitial pneum
onitis; N
SIP = non-specific 
interstitial pneum
onitis; ILD
 = interstitial lung disease; PA
P = pulm
onary alveolar proteinosis; R
D
S = respiratory distress syndrom
e. # B
rasch et al 
2007. 
 41 
Supplemental table 4. Primers used for analysis of ABCA3, SFTPC and SFTPB. The 
sequence of all PCR primers is given in the 5´ to 3´ direction. 
 
ABCA3 gene 
 
A3-4-1 CCAAATCCCCACTCTGCGTG 
A3-5-2 CAGCTGCTTCGCACATCCTG 
A3-6-1 CAAAGCCCTAGAGGATTTGCC 
A3-6-2 CAGACCCAAAGGAGTGACTGC 
A3-7-1 CTCTCCCACTCCACCCTGTTG 
A3-7-2 CTGCTATAAGGACACATGCACACG 
A3-8-1 TCTCATTTGCTGTCAGTGTGTGG 
A3-8-2 CTAAAACACCAAGCCTTTGGACATG 
A3-9-1 CTGCTGGGACAGTCGGACTC 
A3-9-2 CTGACCATCCCTGGTCACAGG 
A3-10-1 CTCTTGGGAAGAACTTTGTGGTCAG 
A3-10-2 GCTGACTTTCCTCCTTCCAGTCC 
A3-11-1 GTGTAGATGGCAAGTGCCAGGAG 
A3-11-2 CAGCTATCCAGCCCACACTCAG 
A3-12-1 CATGCCAACCAAGCAGTGG 
A3-12-2 CTCTCTCTGAACCAGTCCCAAGG 
A3-13-1 CTGCATGGCTGTGTGCATCTAG 
A3-13-2 CTATGAGGTCTCACTGCCGTGC 
A3-14-1 CTAGGCTTGGTTCCTTCTGAGACG 
A3-14-2 GTGCATCTCCTGCCGCTGTG 
A3-15-1 CAGGGTCCTCAGAGGAAATTAGG 
A3-15-2 CTCAGAACCCTGGCTCCTGC 
A3-16-1 CAGCTACGTCAAGGAGAGGTTCC 
A3-16-2 GCTCGTCCAGTATCAGCACCTG 
A3-17-1 CCATCCTTGGAGGACTCAAGC 
A3-17-2 CAGAGGCAACAGACAGGAAGTCTAG 
A3-18-1 CAAGACACATTCATTCTGCTTCAGC 
A3-18-2 GCAGATTCATCTGGGCTGATG 
A3-19-1 GTTCAAGTGTTCTCCTGCCTCTG 
A3-19-2 CTGGGCAACTAGAGTGAAACTCC 
A3-20-1 CATAAGCAGATGCATGAGCAAGC 
A3-20-2 CTCGCAGACTCTCCTCTGCATG 
A3-21-1 GCTGGCGTCACACAGAACAG 
A3-21-2 CATTCGGAACAGCCAAGAACC 
A3-22-1 GTCCCTGATTAGCCATGCTCAG 
A3-22-2 GCAGACACAATGCTCTATCTATGGG 
A3-23-1 GTGCTTGTGCTCTCCCATAAGC 
A3-23-2 CAGCTGGTTCCGGTTCTGC 
A3-24-1 GTCTGAGGACCTCCAAATGCTC 
A3-24-2 CATGAACTGGGCCCATTGC 
A3-25-1 CTCCACACAGCACGGATAAGG 
A3-25-2 CCACTCAGACGCAGAGGAGC 
A3-26-1 GTCTGCCATGTCGCTCATGG 
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A3-26-2 GAGACCATCTGGTGCAGGAGC 
A3-27-1 GATTGGGACGAGAAGCCTTG 
A3-27-2 GCAAAGCAGAGCAGTCTGAGC 
A3-28-1 CTGATTATCAAGGAGCTCTCCAAGG 
A3-28-2 CAAGCCACAGATGCAGCAGC 
A3-29-1 CACTGGCAGGAACCACAG 
A3-29-2 CTCCATCCTGGAGCCACAAG 
A3-30-1 CTGTTCTGCAATTGCTGGGTG 
A3-30-2 GACTCTGCACCAGATGCTGATG 
A3-31-1 GAGAGCCAATGCCTTCCTGTC 
A3-31-2 GTGCTCAGCACTGGAGTCCTC 
A3-32-1 GAGGACTCCAGTGCTGAGCAC 
A3-32-2 GTGACTCCTCTGTGGAAAGAGCC 
A3-33-1 CTATTGCCAGAGGACTCCCAGG 
A3-33-2 GAGTGCCTGGAGAAATTCAACC 
 
 
SFTPB gene 
 
SB-1-1 GCCACAGAAATCTTGTCTCTGACTC 
SB-1-2 TTACCACCTGTCCTGGCTGATG 
SB-2-1 GTTGGAGGAAGCCACAAGTCC 
SB-2-2 GTTAATGCCTAGCACAAAGCAGTG 
SB-3-1 AGAGCTGTCTGACGTCCACATG 
SB-3-2 ATCGCATCCATCCCATTCC 
SB-4-1 AGCTGCATGTGCCTTGGAGTG 
SB-4-2 CTCAGCTCTTCCCTGCTCTGTC 
SB-5-1 TGCCCAACTACTTAACTCCTTGGC 
SB-5-2 CTCCCCATGGGTGGGCACAG 
SB-6-1 AGTGGTCCCTGAGCCCTTG 
SB-6-2 GCTTCGGAGGTGGCTCTAGC 
SB-7-1 CTAGAGCCACCTCCGAAGCC 
SB-7-2 GTGTGAGTTGGGAGAGAGGTGG 
SB-8-1 CTGGACTCTCTGATCCCCAGTG 
SB-8-2 CAGAGGTGTTTGGTTTCTGTCCTC 
SB-9-1 TCTGTGGTCCCACTGCAATG 
SB-9-2 ACATCCTGTCTGCCTGTCTGTG 
SB-10-1 TGATCCAGAGATGTGGAGAGGC 
SB-10-2 GAGTGAGGCCTCTGAGGATCAC 
SB-11-1 GTGGAGTGAGTGCTGTTCTTTCC 
SB-11-2 TCTTCCTGCTTGGGGAGCAG 
 
 
SFTPC gene 
 
SC-1-1 CAGCAAGGAAGGCAGGCAC 
SC-1-2 GAATGGATCTGGATAAGGAAACAGG 
SC-2-1 TCCCTGTCCATCCATCGCATC 
SC-2-2 GACAGTTTCCTATCGCCCATCC 
SC-3-1 GAAAGAGGGAAGCGCATTTGAG 
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SC-3-2 CTCTAGGTTGGGCACGGGAGTC 
SC-4-1 CAGATTCTAGTATGACTCCCGTGC 
SC-4-2 GAGGAACAGTGCTTTACAGGTGAC 
SC-5-1 CTGGTGGCTTCTGACTCTAGCAC 
SC-5-2 GAGTGGGAAGTACCGGTCTGTGAG 
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Supplemental figure 1 
 
 
 
Legend to Supplemental figure. 1: Cellular effects of ABCA3-WT and ABCA3-R288K 
stably expressed in A549 cells. A. ABCA3 mRNA levels analyzed by quantitative real time 
PCR (p<0.001 for WT/mock and p< 0.01 for R288K/mock). B. Western immunoblot analysis 
of HA-tagged ABCA3 in total cell lysates. β-actin was used as a loading control. C. Ratio of 
upper/lower ABCA3 processing form. D. Cell proliferation assay of A549 cells stably 
transfected with ABCA3-WT protein of R288K variant compared to mock control. XTT 
tetrazolium salt was used for absolute quantification. E. Impact of stably transfection method 
on cell cytotoxicity. Therefore lactate dehydrogenase was quantified in cell supernatants. F. 
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Co-immunostaining of HA-tagged ABCA3 with the lysosomal (lamellar body) marker CD63. 
G. Co-immunostaining of HA-tagged ABCA3 with the ER marker calnexin. Scale: 10 µm. 
Merge images present the overlay from green and red fluorescence. All results were expressed 
as mean ± SEM. 
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Supplemental figure 2 
 
 
 
Legend to Supplemental figure 2: Stably expression of ABCA3-WT and ABCA3-R288K 
protein in HEK293 cells: A: Relative mRNA levels of HEK293 stably expressing ABCA3-
WT and ABCA3-R288K analyzed by quantitative real time PCR compared to mock control. 
*P<0.05. B: Immunoblot analysis of ABCA3-WT and ABCA3-R288K stably expressed in 
HEK293 cells. ß-actin was used as loading control. 
Appendix 
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ABSTRACT 
Background: Interstitial lung diseases (ILD) comprise disorders of mostly unknown cause. 
Among the few molecularly defined entities, mutations in the gene encoding the ATP-
binding cassette (ABC), subfamily A, member 3 (ABCA3) lipid transporter represent the 
main cause of inherited surfactant dysfunction disorders, a subgroup of ILD. Whereas many 
cases are reported, specific methods to functionally define such mutations are rarely 
presented.  
Materials and methods: In this study, we exemplarily utilized a set of molecular tools to 
characterize the mutation K1388N, which had been identified in a patient suffering from ILD 
with lethal outcome. We also aimed to correlate in-vitro and ex-vivo findings.  
Results: We found that presence of the K1388N mutation did not affect protein expression, 
but resulted in functional impairment of ABCA3 as demonstrated by reduced transport of 
dipalmitoyl-phosphatidylcholine (PC 32:0) and malformed lamellar bodies. 
Conclusions: Here we present a set of tools useful for categorizing different ABCA3 
mutations according to their impact upon ABCA3 activity. Knowledge of the molecular 
defects and close correlation of in-vitro and ex-vivo data will allow us to define groups of 
mutations that can be targeted by small molecule correctors for restoring impaired ABCA3 
transporter in the future. 
Word count abstract: 194  
Word count total: 2858 
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INTRODUCTION 
 ATP-binding cassette (ABC), subfamily A, member 3 (ABCA3) is an intracellular 
lipid transporter containing two transmembrane domains each consisting of six membrane 
helices and two nucleotide binding domains (NBDs) hydrolyzing ATP.1,2 In the lungs the 
transporter localizes to the outer membrane of lamellar bodies (LBs) of type II pneumocytes. 
LBs derive from lysosomal origin and serve as production and storage organelles for 
pulmonary surfactant, which is then secreted into the alveolar space. ABCA3 transports 
phospholipids and cholesterol into the LB lumen and is therefore essential for LB biogenesis 
and homeostasis of pulmonary surfactant and normal lung function.1,3,4 
All these processes are delicately disturbed by sequence variations of ABCA3. A 
broad spectrum of mutations has recently been shown to cause pulmonary ABCA3 deficiency 
followed by early death or fibrotic lung disease in survivors.5-8 
The deficiency of another ABC transporter, ABCC7 (Cystic fibrosis transmembrane 
conductance regulator, CFTR), shows many interesting similarities to ABCA3 deficiencies. 
The availability of cellular assays to characterize the CFTR phenotype in-vitro and tight 
correlations to ex-vivo patient data have led to the precise molecular classification of CFTR 
mutations,9,10 successful correction of mutations in cell models with small molecules 
identified by high throughput screening and rapid transfer into patients.11,12 
To acquire similar knowledge for ABCA3 deficiency, many intermediate steps need 
to be realized including stable and readily available cellular models, assays to characterize 
the cellular phenotype of the different mutations, and in particular close correlation of such 
measurements to ex-vivo patient data. ABCA3 mutations, which were predicted to result in 
truncated or non-functional proteins were classified as “null/null” mutations and affected 
infants presented respiratory failure at birth and all had died by 1 year of age if not lung 
transplanted.8 Mutations affecting protein function in any way were termed “other”.8 From a 
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cellular perspective mutations were previously distinguished between those with abnormal 
localization of the ABCA3 protein in the cells and those with ATP hydrolysis defects.1 The 
major role of ABCA3 in LB biogenesis and surfactant lipid synthesis, i.e. dipalmitoyl-
phosphatidylcholine (PC 32:0) content of the cells, must also be considered.13,14 
Such cellular classifications of ABCA3 mutations have to be linked to the clinical 
characterizations of affected subjects carrying different types of ABCA3 gene sequence 
variations to build up a consistent and reliable model. 
In this study we used a broad range of experiments to assess in-vitro and ex-vivo 
characteristics of wild type and a mutated ABCA3 protein. Our results demonstrate a very 
close connection between the results obtained in the cell model applied and the findings from 
a patient harbouring the same homozygous ABCA3 variant. The molecular tools defined here 
allow a classification of ABCA3 mutations; this will be of use when searching for new 
molecules to restore genetically disturbed ABCA3 function. 
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MATERIALS and METHODS (see detailed descriptions in the supplemental material) 
Plasmids and antibodies 
ABCA3 cDNA (NM_001089) fused to a C-terminal HA-tag and puromycin resistance gene 
were cloned into pT2/HB transposon vector (Addgene, Cambridge, United States, plasmid 
#26557). ABCA3-K1388N point mutation (c. 4164G>C; AAG/AAC) was introduced using 
Q5® site-directed mutagenesis kit (NEB, Massachusetts, United States) with following 
primers: K1388N-for 5’-AGCTCTCCAACGTGTACGAGC-3’ and K1388N-rev 5’-
CCTTGATAATCAGAGGTGTG-3’. pCMV(CAT)T7-SB100 transposase was ordered from 
Addgene (plasmid #34879).  
Used antibodies are listed in the supplement. 
 
Cell culture 
A549 cells were purchased from the German Collection of Microorganisms and Cell Cultures 
(DSMZ, Braunschweig, Germany) and maintained in RPMI 1640 medium (Gibco, 
Darmstadt, Germany) supplemented with 10% fetal bovine serum (FBS) (Sigma, 
Taufkirchen, Germany) at 37°C with 5% CO2. 
 
Generation of stable cell clones 
ABCA3-HA wild type (WT) and K1388N variation were stably transfected using the 
“Sleeping Beauty” transposon system.15 Therefore A549 cells were cotransfected with 
pCMV(CAT)T7-SB100 and pT2/HB-puro-ABCA3-HA WT or K1388N variation using X-
tremeGENE HP DNA transfection reagent (Roche, Mannheim, Germany). Selection of stable 
cells was started by addition of 1µg/ml puromycin. 
 
Viability and cytotoxicity assay 
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Cell viability was assessed by specific cleavage of 2,3-bis (2-methoxy-4-nitro-sulfophenyl)-
2H-tetrazolium-5-carboxyanilide (XTT, Sigma) in the presence of phenazine methosulfate. 
Absorbance was measured at 490 nm and 650 nm using a spectrophotometer.  
For cytotoxic effects of stable transfection, the amount of lactate dehydrogenase (LDH) was 
determined in cell supernatants according to the manufacturer’s instructions (Promega, 
Mannheim, Germany). 
 
Real-time PCR/ Immunoblotting/ Immunofluorescence staining/ Oil Red O staining 
Real-time PCR, immunoblotting, immunofluorescence staining and oil red O staining were 
performed as previously described.16 To determine cellular oil red O volume, Z stacks image 
series were generated with an Olympus IX81/Fluoview FV1000 confocal laser scanning 
microscope (Olympus, Tokyo, Japan). Data were analysed with the 3D object counter 
software plugin in ImageJ. 
 
Glycosylation analysis/ Lipid analysis / Electron microscopy 
Glycosylation analysis was done as previously described.1 Lipid analysis was performed as 
previously reported.14 Electron microscopy was performed as described.7 
 
Vesicle volume 
A549 cells containing either ABCA3-WT or K1388N variation were immunostained against 
HA-tag and imaged with an Olympus IX81/Fluoview FV1000 confocal laser scanning 
microscope. Diameter of ABCA3-HA containing vesicle was determined with ImageJ 
software. Volumes of 60 different randomly chosen vesicles were calculated, thus analysing 
20 vesicles per condition and experiment. 
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Immunohistochemistry 
Slides were pretreated with Target Unmasking Fluid (Panpath, Amsterdam, The Netherlands) 
at 90°C followed by an incubation of primary antibody against ABCA3 protein (diluted 
1:1800) for 60 min at RT. Detection was done using Vectastain ABC-Kit Elite Universal 
(Vector Laboratories, Burlingame, United States) and AEC+ chromogen as substrate (Dako, 
Santa Clara, United States). Slides were counterstained with Hematoxylin Gill’s Formula 
(Vector Laboratories). Microscopic pictures were taken with a Leica DM4000 (Leica, 
Wetzlar, Germany) 
 
In-vivo and ex-vivo analysis of patient materials 
Bronchoalveolar lavage (BAL), lung tissue and blood were investigated from an infant. 
Informed consent of the parents and approval of the institutional review board (EK 026-06) 
were obtained. Analysis of data was performed under the FP7-305653 project chILD-EU (EK 
111-13). 
 
Statistical analysis 
Comparison of two groups was done using Student’s t-test. Comparisons of multiple groups 
were done using one-way repeated measure ANOVAs with Tuckey’s post hoc test. Lipid 
contents were analysed using two-way ANOVA with Sidak’s post hoc test. Ratios of 
phosphatidylcholine species were analysed using one-sample t test comparing to the 
hypothetical value of 1. Significance levels for ratios were corrected according to Benjamini 
and Hochberg.17 Results were presented as mean ± S.E.M. of a minimum of three different 
experiments. P-values < 0.05 were considered to be statistically significant. 
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RESULTS 
The homozygous K1388N variant of ABCA3 protein leads to complete ABCA3 
deficiency resulting in lethal interstitial lung disease 
The homozygous ABCA3 variation K1388N was found in a patient presenting typically for 
complete ABCA3 deficiency with severe respiratory distress (Figure 1 A-B), a brief period of 
recovery with interstitial lung disease and the typical histological pattern of chronic 
pneumonitis of infancy and abnormal LB on electron microscopy (Figure 1 C-F), progressing 
to respiratory insufficiency and death at the age of 9 weeks. BAL content of SP-C was 
reduced and showed some higher molecular weight forms at relatively low concentration 
(Figure 1 G). The K1388N mutation was predicted to be malign and not tolerated by the 
algorithms Polyphen and SIFT. A topological model of ABCA3 protein predicts a 
localisation of K1388N variant in proximity to the nucleotide-binding domain 2 (NBD2) 
(Figure 1 H), which comprises two Walker motives.18 Furthermore partial alignment of 
codons 1348-1429 of the ABCA3 coding sequence demonstrates an extremely conserved 
region including Lys1388 between different species (Figure 1 I). 
 
Impaired intracellular processing of K1388N variation 
A549 lung epithelial cells stably expressing ABCA3-WT and ABCA3-K1388N variant 
showed an increased ABCA3-mRNA expression of 200-fold as compared to mock transfected 
cells (Figure 2 A). Furthermore cell growth and proliferation were unaffected in both cell 
lines either expressing ABCA3-K1388N or ABCA3-WT protein in comparison to mock 
control cells (Figure 2 D+E). But intracellular processing examined by Western 
immunoblotting revealed an alteration of K1388N variant compared to wild type protein 
(Figure 2 B). Both proteins were present as the 190 and 150 kDa processing forms, but band 
intensities differed. The 190 kDa processing form of the mutated K1388N protein was 
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enriched considerably. Therefore the band ratio of 190 kDa to 150 kDa was increased up to 
20-fold in ABCA3-K1388N expressing cells as compared to A549 cells with ABCA3-WT 
protein (Figure 2 C). Intracellular processing examined by co-localization studies with the 
immunofluorescent marker CD63, a marker for late endosomes and lamellar bodies, revealed 
localization within CD63 positive vesicles of both wild type and K1388N protein variant 
(Figure 2 G). Furthermore neither ABCA3 wild type protein nor K1388N mutated protein 
showed a co-localization with the ER-resident chaperone calnexin (Figure 2 H). Additional 
N-glycosylation studies revealed that ABCA3 wild type protein as well as K1388N mutated 
protein showed equal processing from high-mannose oligosaccharides to complex-type 
oligosaccharides (Figure 2 F). This further supports the view that both proteins undergo 
correct folding in the ER and further processing within the Golgi apparatus. 
 
K1388N variation results in smaller lamellar bodies with abnormal morphology 
Analysis of ABCA3-K1388N containing lamellar bodies revealed a significant decrease of 
volume compared to lamellar body volume of A549 cells expressing ABCA3-WT (Figure 3 
A). Lamellar body morphology of ABCA3-K1388N expressing cells was altered as 
compared to ACBCA3-WT expressing cells. Mock control cells contained no lamellar bodies 
(Figure 3 B, left), whereas ABCA3-WT expressing cells showed well-structured lamellar 
bodies with concentric membranes arranged in parallel (Figure 3 B, middle). ABCA3-
K1388N containing lamellar bodies showed abnormal morphology with fried-egg-like 
structures (Figure 3 B, right). Additional analysis of lung tissue from a patient carrying 
homozygous K1388N variant showed a very weak expression and a high dispersed ABCA3 
protein in type II pneumocytes, whereas ABCA3 is strongly expressed in healthy lung tissue 
(Figure 3 C). Control tissue displayed a typical pattern of LBs with ring-like structures, 
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whereas LBs in lung tissue with ABCA3-K1388N variant were absent (compare Figure 3 C 
left to right). 
Reduction of phosphatidylcholine and dipalmitoyl-phosphatidylcholine content due to 
K1388N mutation 
Measurement of intracellular lipid classes from A549 cells expressing ABCA3-K1388N 
mutated protein exhibits a reduction of phosphatidylcholine content as the major lipid in 
surfactant compared to A549 cells expressing ABCA3-WT (Figure 4 A, left). Other lipid 
classes were not affected by this mutation (Supplemental figure 1 A, right). Free cholesterol 
content and cholesteryl esters were significantly reduced in K1388N expressing A549 cells, 
whereas lipid droplet volume and lipid droplet number showed no differences compared to 
A549 expressing ABCA3-WT cells (Supplemental figure 2 A+B). On the detailed PC species 
level short-chained lipid contents were reduced in contrast to long-chained species, which 
were increased (Supplemental figure 1 B, right). PC 32:0 as the most abundant PC species in 
surfactant was also reduced to a third (Figure 4 A, right). These findings can also be verified 
in BAL isolated from the homozygous carrier of the K1388N variant. PC content was also 
lowered as compared to BALs of control group (Figure 4 B, left). Additionally 
sphingomyelin (SPM), PE based plasmalogens (PE P) and phosphatidylglycerol (PG) content 
were decreased, whereas ceramide (Cer) content was slightly increased (Supplemental figure 
1 A, left). Furthermore molecular PC species composition showed a similar distribution with 
a lower fraction of PC 30 and 32 species and more PC 36 and 38 species compared to 
controls (Supplemental figure 1 B, left). PC 32:0 content of a patient with K1388N variation 
was diminished by half of it as compared to controls (Figure 4 B, right).  
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DISCUSSION 
In this study we present a broad set of experiments to assess the function of wild type 
ABCA3 protein in comparison to the specific features of ABCA3 with the mutation K1388N, 
which was found in a patient suffering from respiratory distress syndrome (Table 1). Our goal 
was to establish different molecular tools for the characterization and classification of newly 
described ABCA3 variants and to test the tightness of correlation between the in-vitro data 
raised in stably transfected A549 cells and ex-vivo data collected from an affected subject. 
The K1388N variation of the ABCA3 transporter caused severe respiratory neonatal 
distress followed by a brief period of recovery with interstitial lung disease, progressing to 
respiratory insufficiency and death at the age of 9 weeks. Obviously, this newly described 
homozygous mutation led to complete ABCA3 deficiency, which is incompatible with life.19 
In-silico analysis predicted these damaging consequences of this mutation, which is localized 
in proximity of the functional critical nucleotide-binding domain 2 (NBD2). Lys1388 is a 
highly conserved position among various species, further supporting its role for normal 
function of ABCA3 protein. 
It could be shown for some ABC transporters like ABCC7 (CFTR) that certain 
mutations induce intracellular mislocalization of the protein.20,21 Our data clearly show that 
ABCA3-K1388N is correctly localized to lamellar bodies and was not retained in the ER. 
The processing of its oligosaccharides from the high mannose type to the complex type 
showed trafficking through ER and Golgi apparatus. This follows the cellular path of 
ABCA3-WT protein, which also passes through these two organelles. Nevertheless, cellular 
processing of K1388N is impaired compared to WT protein, as the 190 kDa processing form 
of the protein is enriched in A549 cells stably expressing the variant. Previous studies showed 
that N-glycosylation is essential for the stability of ABCA3 protein.18 Introducing a further 
N-glycosylation site due to another asparagine instead of a lysine on position 1388 may lead 
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to elevated protein instability. Thus several lines of evidence support impaired processing of 
the K1388N variant, resulting in less active transporter available and leading to reduced 
volume and structurally altered LBs. Whereas ABCA3-WT expression led to the prominent 
induction of well-shaped LBs in A549 cells, expression of ABCA3-K1388N induced the 
formation of abnormal LBs. This notion supports the concept that ABCA3 wild type function 
is indispensable for normal LB production and that this ability is severely impaired in the 
K1388N variant. 
Analysis of lung tissue from the child carrying the homozygous K1388N variant 
demonstrated an altered expression pattern of ABCA3 protein in type II pneumocytes. This 
was identified by a weak immunohistochemical staining of ABCA3 and only rather small 
protein agglomerations compared to normal well-shaped LBs detectable in tissues from 
healthy children. Similarly, in lung tissue from the affected child, the characteristic fried-egg-
shaped and functionally inactive LBs were demonstrated. Together, we show a close 
recapitulation of morphological LB dysfunction in our stable cell model and the patient. 
To directly assess the functional impact of the K1388N variant compared to ABCA3-
WT protein, lipid composition was measured. Previous studies showed that the amount of PC 
32:0 is significantly reduced in BALs of children carrying interstitial lung disease causing 
mutations on both alleles.13,14 Both total PC and PC 32:0 were reduced in A549 cells stably 
expressing ABCA3-K1388N and in BAL of the child with homozygous K1388N variant 
compared to respective controls. This provides direct in-vitro and ex-vivo evidence for 
reduced ABCA3 lipid transporter function. Furthermore the K1388N variant led to an 
elevation of long-chained PC species content in both A549 cells and in BAL of the patient 
compared to controls.  
Whereas a major strength of our study was to correlate the in-vitro data from our 
model system for lung epithelial cells and ex-vivo data from a patient in relation to the 
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K1388N variant, there are some weaknesses. We assessed intracellular lipid composition; 
however the surfactant lipids are usually exocytosed into the alveolar space in-vivo and thus 
represent just a subfraction. We found a tight correlation for PC 32:0 which, as the major 
surfactant phosphatidylcholine species is enriched in lamellar bodies.22 We expected this in-
vitro, but the sensitivity of mass spectrometry to determine unlabelled PC 32:0 directly in the 
supernatant of cells cultured in dishes was too low. However an enrichment of intracellular 
PC 32:0 was shown in our model system.  
Patient-derived type-II-pneumocytes would be most helpful for in-vitro studies on 
specific mutations; however such lines are not available for most rare mutations.23,24 The 
A549 cell-line used here was formerly derived from lung adenocarcinoma and lost its ability 
to form LBs with normal structure and characteristic surfactant composition.25 However, this 
may even be of advantage to demonstrate transport of surfactant lipids into such organelles 
in-vitro. Here we show that the expression of ABCA3-WT protein at a constantly high level 
led to the formation of well-shaped LBs with an enrichment of PC and PC 32:0 content. This 
morphological feature has previously been shown for HEK293 cells3,7 and represents an 
elegant functional assay for intact ABCA3 transporter activity. 
Collecting further clinical data from patients with this mutation linked to laboratory-
based experiments to understand how a particular mutation works will be necessary and will 
be of use for allocating mutations into groups with the same class of a molecular defect in the 
future. This is essential in face of the large number of different ABCA3 mutations identified, 
as those from the same class might be targeted by the same group of small molecules for 
restoring the wild type function of the protein.  
In summary, we characterized the K1388N variant of ABCA3 as a processing 
mutation with normal intracellular localisation and a reduced lipid transporter activity for PC 
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32:0. This led to LBs with a reduced volume and an abnormal morphology. Thus this 
mutation can be classified as a functional mutation.  
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LEGENDS TO THE FIGURES 
Figure 1: Clinical characterization of a child carrying homozygous K1388N variation of 
ABCA3 protein. A. Chest x-ray. Initial chest x-ray showing homogenous fine reticular 
ground glass opacification. B. Clinical course of the neonate (ECMO = extra corporal 
membrane oxygenation). C. Lung biopsy. Lung biopsy showing the pattern of chronic 
pneumonitis of infancy; note increased presence of eosinophils (indicated by small block 
arrows, scale indicates 100 µm); for comparison a normal biopsy is given in D.. E. and F. 
show electron micrographs demonstrating plenty, albeit abnormal lamellar bodies in type II 
cells. Note the lack of lamellar structures and the presence of aggregates of dense material 
located marginally. G. Western blotting of a tracheobronchial aspirate (SP-B and SP-C), 
indicated amount of total protein of lavage added per lane and the respective standards (STD) 
of the patient obtained at the age of 5 weeks of life, 4.8 weeks after the administration of a 
single dose of exogenous surfactant. After SDS-PAGE and transfer, the membranes were 
probed with antibodies against SP-B and SP-C. Molecular weights (kDa) are indicated on the 
left side. All bands were analyzed under non-reducing conditions. SP-B was detected in large 
amounts (compare to standard STD of 8 ng applied to lane 2). In addition to the typical bands 
at 18 kDa some lower bands (monomers or degradation products), as well as higher 
molecular forms were observed. SP-C was detected in relatively smaller amounts making up 
less than 10% of the total amount (usually about 50%). Of interest was the presence of 
several higher molecular weight bands; this pattern is typically seen in patients with alveolar 
proteinosis. H. Schematic representation of ABCA3 protein with different sequence motifs 
and correct orientation. The K1388N mutation is shown as red filled hexagon. I. Partial 
amino acid alignment of ABCA3 sequences (codons 1348-1429). Alignment is showing that 
Lys1388 (indicated by red arrow) is extremely conserved. 
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Figure 2: Cellular effects of ABCA3-WT and ABCA3-K1388N stably expressed in A549 
cells. A. ABCA3 mRNA levels analyzed by quantitative real time PCR (p<0.001 for 
WT/mock and K1388N/mock). B. Western immunoblot analysis of HA-tagged ABCA3 in 
total cell lysates. β-actin was used as a loading control. C. Ratio of upper/lower ABCA3 
processing form (p<0.5). D. Cell proliferation assay of A549 cells stably transfected with WT 
and K1388N mutated ABCA3 protein compared to mock control. XTT tetrazolium salt was 
used for absolute quantification. E. Impact of stably transfection method on cell cytotoxicity. 
Therefore lactate dehydrogenase was quantified in cell supernatants. F. N-Glycosylation of 
ABCA3-HA WT and K1388N protein. The noncleaved 190 kDa ABCA3-HA protein is fully 
deglycosylated by PNGase F causing a shift in electrophoretic mobility to 180 kDa. Endo H 
digestion results in a separation of Endo H-sensitive 180 kDa ABCA3-HA protein 
(containing only high-mannose oligosaccharides) and Endo H-insensitive 190 kDa ABCA3-
HA protein (with complex-type oligosaccharides). G. Co-immunostaining of HA-tagged 
ABCA3 with the lysosomal (lamellar body) marker CD63. H. Co-immunostaining of HA-
tagged ABCA3 with the ER marker calnexin. (Scale: 10µm) 
Figure 3: Impact of ABCA3-K1388N variant on lamellar body volume and 
morphogenesis. A. Left: immunofluorescence staining of HA-tagged ABCA3-WT and 
ABCA3-K1388N protein included in vesicles (scale: 10 µm). Vesicle volume was calculated 
based on diameter. Right: mean values of vesicle volumes containing either ABCA3-WT or 
ABCA3-K1388N protein. ***P<0.001. B. Electron microscopy of lamellar bodies showing 
mock control (left), ABCA3-WT (middle) and ABCA3-K1388N expressing A549 cells 
(right), respectively. Mock control cells contained no lamellar bodies, whereas ABCA3-WT 
transfected cells obtained morphological well-shaped LB with concentric membranes 
arranged in parallel (middle, black arrows). ABCA3-K1388N transfected A549 cells showed 
abnormal, fried-egg like structured lamellar bodies (right, black arrows). Scale: 0.5 µm. C. 
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Immunohistochemical staining of ABCA3 protein in lung tissues. Lung tissue of a healthy 
control patient expressing ABCA3 protein (left., red staining). ABCA3 expression shows 
strong staining intensity and typical pattern of ring-like structures located in the cytoplasm of 
type II pneumocytes. Right: ABCA3 protein expression in lung tissue of patient with 
homozygous ABCA3-K1388K protein variant. Very weak staining intensity and diffuse 
distribution of ABCA3 protein in type II pneumocytes can be detected. (Scale: 50 µm).  
Figure 4: PC and PC 32:0 content. A. Intracellular PC and PC 32:0 content of A549 cells 
carrying ABCA3-K1388N variant compared to that in cells expressing ABCA3-WT protein. 
**P<0.01, ***P<0.001. B. PC and PC 32:0 content in BAL of patient with homozygous 
ABCA3-K1388N mutation compared to control group. 
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Figure 3 
 
 27 
Figure 4 
Table 1: C
riteria and m
olecular tools used to characterize the A
B
C
A
3 transporter 
  
28 
 C
riterion for classification 
 
M
olecular tool 
M
ock transfected 
cells / H
ealthy 
controls 
A
B
C
A
3-W
T
 cells 
D
ifference 
P-value 
A
B
C
A
3-K
1388N
 
cells / Patient 
D
ifference 
P-value 
Processing 
(R
atio 190 kD
a/150 kD
a form
) 
W
estern B
lot 
n.a. 
2.26 ± 0.30 
n.a. 
20.30 ± 3.55 
0.0316** 
Intracellular protein localization 
Im
m
unofluorescence 
n.a. 
C
o-localization 
w
ith C
D
63 
- 
C
o-localization w
ith 
C
D
63 
- 
 
Im
m
unohistochem
istry 
in patient tissue 
sections 
Strong and ring-like 
A
B
C
A
3 staining in 
type II 
pneum
ocytes 
n.a. 
- 
W
eak and dispersed 
A
B
C
A
3 staining 
pattern in type II 
pneum
ocytes 
- 
Intracellular trafficking 
N
-glycosylation 
analysis 
n.a. 
Trafficking through 
ER
 and G
olgi 
apparatus 
- 
Trafficking through 
ER
 and G
olgi 
apparatus 
- 
Lam
ellar body volum
e 
Im
m
unofluorescence 
n.a. 
2.47 ± 0.16 
n.a. 
1.38 ± 0.10 
<0.0001** 
Lam
ellar body m
orphogenesis 
Electron m
icroscopy 
Scarce or no 
lam
ellar bodies 
W
ell-shaped 
lam
ellar bodies 
w
ith concentric 
m
em
branes 
- 
A
bnorm
al fried-egg 
like shaped lam
ellar 
bodies 
- 
Table 1: C
riteria and m
olecular tools used to characterize the A
B
C
A
3 transporter 
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Phosphatidylcholine content  
A
549 cells (nm
ol/m
g protein) (n=9) 
90.11 ± 0.97 
118.25 ± 6.52 
0.0061* 
94.31 ± 1.57 
0.1340* 
0.0101+ 
Phosphatidylcholine content  
B
A
L (%
 of all analyzed lipids) 
89.3 ± 0.8 
n.a. 
n.a. 
37.5 
n.a. 
D
ipalm
itoyl-phosphatidylcholine 
(PC
 32:0) content  
A
549 cells (nm
ol/m
g protein) 
(n=9) 
4.52 ± 0.05 
6.74 ± 0.61 
0.0235* 
2.70 ± 0.09 
<0.0001* 
0.0003+ 
D
ipalm
itoyl-phosphatidylcholine 
(PC
 32:0) content  
B
A
L (%
 of all analyzed lipids) 
M
ass spectrom
etry 
45.8 ± 1.1 
n.a. 
n.a. 
24.5 
n.a. 
 n.a.= not available, *: P-values com
pared to control. **: P-values com
pared to A
B
C
A
3-W
T. +: P-values A
B
C
A
3-K
1388N
 com
pared to A
B
C
A
3-
W
T. M
ean values (± S.E.M
.) are displayed. 
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SUPPLEMENTAL MATERIAL 
Supplemental Methods 
Antibodies 
The following antibodies were used: rabbit anti-HA (Sigma, Taufkirchen, Germany), rat anti-
HA (Roche, Mannheim, Germany), mouse anti-CD63 (Abcam, Cambridge, United 
Kingdom), mouse anti-calnexin (Novus Biologicals, Cambridge, United Kingdom), chicken 
horse radish peroxidase (HRP)-conjugated anti-β-Actin (Santa Cruz, Heidelberg, Germany), 
Alexa Fluor 488 goat anti-rabbit IgG and Alexa Fluor 555 goat anti-mouse IgG (Life 
Technologies, Darmstadt, Germany), mouse anti-ABCA3 antibody (Seven Hills Bioreagents, 
Cincinnati, United States), rabbit anti-rat IgG (H+L) HRP (Southern Biotech, Eching, 
Germany). 
 
In-vivo and ex-vivo analysis of patient materials 
Mature neonate (41 week of gestation), APGAR 7 /8 after 5/ 10 min, oxygen 
supplementation, intubation first day of life, pulmonary hypertension (NO treatment), day 3 
of life ECMO for one week, with improving oxygenation and successful decanulation, high 
frequency oscillatory ventilation (Fi02 0.6), treatment with surfactant with only brief 
improvement, slow deterioration of respiratory situation with increasing pulmonary arterial 
pressures, erythromycin for 7 days, lung biopsy with chronic pneumonitis of infancy pattern 
and tissue eosinophilia. A diagnostic BAL was taken prior to surfactant application. 
Methylprednisolone and hydroxychloroquine over 4 weeks without significant improvement. 
The respiratory situation deteriorated slowly but steadily and the patient died at age of 9 
weeks. The ABCA3 variation K1388N (c.4164G>C; AAG/AAC) was found in a patient 
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carrying this mutation in a homozygous state. SFTPB and SFTPC were without sequence 
variation. 
 
Primers used for analysis of ABCA3, SFTPC and SFTPB. The sequence of all PCR 
primers is given in the 5´ to 3´ direction. 
ABCA3 gene 
 
A3-4-1 CCAAATCCCCACTCTGCGTG 
A3-5-2 CAGCTGCTTCGCACATCCTG 
A3-6-1 CAAAGCCCTAGAGGATTTGCC 
A3-6-2 CAGACCCAAAGGAGTGACTGC 
A3-7-1 CTCTCCCACTCCACCCTGTTG 
A3-7-2 CTGCTATAAGGACACATGCACACG 
A3-8-1 TCTCATTTGCTGTCAGTGTGTGG 
A3-8-2 CTAAAACACCAAGCCTTTGGACATG 
A3-9-1 CTGCTGGGACAGTCGGACTC 
A3-9-2 CTGACCATCCCTGGTCACAGG 
A3-10-1 CTCTTGGGAAGAACTTTGTGGTCAG 
A3-10-2 GCTGACTTTCCTCCTTCCAGTCC 
A3-11-1 GTGTAGATGGCAAGTGCCAGGAG 
A3-11-2 CAGCTATCCAGCCCACACTCAG 
A3-12-1 CATGCCAACCAAGCAGTGG 
A3-12-2 CTCTCTCTGAACCAGTCCCAAGG 
A3-13-1 CTGCATGGCTGTGTGCATCTAG 
A3-13-2 CTATGAGGTCTCACTGCCGTGC 
A3-14-1 CTAGGCTTGGTTCCTTCTGAGACG 
A3-14-2 GTGCATCTCCTGCCGCTGTG 
A3-15-1 CAGGGTCCTCAGAGGAAATTAGG 
A3-15-2 CTCAGAACCCTGGCTCCTGC 
A3-16-1 CAGCTACGTCAAGGAGAGGTTCC 
A3-16-2 GCTCGTCCAGTATCAGCACCTG 
A3-17-1 CCATCCTTGGAGGACTCAAGC 
A3-17-2 CAGAGGCAACAGACAGGAAGTCTAG 
A3-18-1 CAAGACACATTCATTCTGCTTCAGC 
A3-18-2 GCAGATTCATCTGGGCTGATG 
A3-19-1 GTTCAAGTGTTCTCCTGCCTCTG 
A3-19-2 CTGGGCAACTAGAGTGAAACTCC 
A3-20-1 CATAAGCAGATGCATGAGCAAGC 
A3-20-2 CTCGCAGACTCTCCTCTGCATG 
A3-21-1 GCTGGCGTCACACAGAACAG 
A3-21-2 CATTCGGAACAGCCAAGAACC 
A3-22-1 GTCCCTGATTAGCCATGCTCAG 
A3-22-2 GCAGACACAATGCTCTATCTATGGG 
A3-23-1 GTGCTTGTGCTCTCCCATAAGC 
A3-23-2 CAGCTGGTTCCGGTTCTGC 
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A3-24-1 GTCTGAGGACCTCCAAATGCTC 
A3-24-2 CATGAACTGGGCCCATTGC 
A3-25-1 CTCCACACAGCACGGATAAGG 
A3-25-2 CCACTCAGACGCAGAGGAGC 
A3-26-1 GTCTGCCATGTCGCTCATGG 
A3-26-2 GAGACCATCTGGTGCAGGAGC 
A3-27-1 GATTGGGACGAGAAGCCTTG 
A3-27-2 GCAAAGCAGAGCAGTCTGAGC 
A3-28-1 CTGATTATCAAGGAGCTCTCCAAGG 
A3-28-2 CAAGCCACAGATGCAGCAGC 
A3-29-1 CACTGGCAGGAACCACAG 
A3-29-2 CTCCATCCTGGAGCCACAAG 
A3-30-1 CTGTTCTGCAATTGCTGGGTG 
A3-30-2 GACTCTGCACCAGATGCTGATG 
A3-31-1 GAGAGCCAATGCCTTCCTGTC 
A3-31-2 GTGCTCAGCACTGGAGTCCTC 
A3-32-1 GAGGACTCCAGTGCTGAGCAC 
A3-32-2 GTGACTCCTCTGTGGAAAGAGCC 
A3-33-1 CTATTGCCAGAGGACTCCCAGG 
A3-33-2 GAGTGCCTGGAGAAATTCAACC 
 
 
SFTPB gene 
 
SB-1-1 GCCACAGAAATCTTGTCTCTGACTC 
SB-1-2 TTACCACCTGTCCTGGCTGATG 
SB-2-1 GTTGGAGGAAGCCACAAGTCC 
SB-2-2 GTTAATGCCTAGCACAAAGCAGTG 
SB-3-1 AGAGCTGTCTGACGTCCACATG 
SB-3-2 ATCGCATCCATCCCATTCC 
SB-4-1 AGCTGCATGTGCCTTGGAGTG 
SB-4-2 CTCAGCTCTTCCCTGCTCTGTC 
SB-5-1 TGCCCAACTACTTAACTCCTTGGC 
SB-5-2 CTCCCCATGGGTGGGCACAG 
SB-6-1 AGTGGTCCCTGAGCCCTTG 
SB-6-2 GCTTCGGAGGTGGCTCTAGC 
SB-7-1 CTAGAGCCACCTCCGAAGCC 
SB-7-2 GTGTGAGTTGGGAGAGAGGTGG 
SB-8-1 CTGGACTCTCTGATCCCCAGTG 
SB-8-2 CAGAGGTGTTTGGTTTCTGTCCTC 
SB-9-1 TCTGTGGTCCCACTGCAATG 
SB-9-2 ACATCCTGTCTGCCTGTCTGTG 
SB-10-1 TGATCCAGAGATGTGGAGAGGC 
SB-10-2 GAGTGAGGCCTCTGAGGATCAC 
SB-11-1 GTGGAGTGAGTGCTGTTCTTTCC 
SB-11-2 TCTTCCTGCTTGGGGAGCAG 
 
 
SFTPC gene 
 
SC-1-1 CAGCAAGGAAGGCAGGCAC 
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SC-1-2 GAATGGATCTGGATAAGGAAACAGG 
SC-2-1 TCCCTGTCCATCCATCGCATC 
SC-2-2 GACAGTTTCCTATCGCCCATCC 
SC-3-1 GAAAGAGGGAAGCGCATTTGAG 
SC-3-2 CTCTAGGTTGGGCACGGGAGTC 
SC-4-1 CAGATTCTAGTATGACTCCCGTGC 
SC-4-2 GAGGAACAGTGCTTTACAGGTGAC 
SC-5-1 CTGGTGGCTTCTGACTCTAGCAC 
SC-5-2 GAGTGGGAAGTACCGGTCTGTGAG 
 
 
Legends to Supplemental Figures 
 
Supplemental Figure 1. Lipid composition and PC species content. A. Left: lipids (% of 
all analyzed lipid classes) in BAL of patient carrying K1388N variant compared to control 
group (n=11). Right: Intracellular lipid content (nmol/mg protein) of A549 cells stably 
expressing K1388N variant compared to A549 cells expressing ABCA3-WT protein. 
****P<0.0001. Abbreviations: PC: phosphatidylcholine; SPM: sphingomyelin with 
dihydrosphingomyelin; PE: phosphatidylethanolamine; PE P: PE based plasmalogens; PS: 
phosphatidylserine; PG: phosphatidylglycerol; PI: phosphatidylinositol; LPC: 
lysophosphatidylcholine; Cer: ceramide. B. PC species content of lipids in BAL of patient 
carrying K1388N mutation compared to control group (left) and in A549 cells stably 
expressing ABCA3-K1388N compared to cells with ABCA3-WT expression (right). For 
better depiction ratio of lipid content relative to control group and WT respectively was 
calculated. A ratio below 1 indicates a decrease of the respective PC species compared to 
control group or WT, while a ratio above 1 indicates an increase in comparison to control 
group or WT. *: P-values are adjusted with Benjamini and Hochberg correction for multiple 
comparisons. 
Supplemental Figure 2: A. Free cholesterol content and cholesteryl ester in A549 cells 
expressing either ABCA3-WT or ABCA3-K1388N mutated protein. *P<0.05, **P<0.001. B. 
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Lipid droplet formation in epithelial lung cells expressing ABCA3-WT and ABCA3-K1388N. 
Lipid droplets per cell (left) and lipid droplet volume per cell were calculated with 3D object 
counter software plugin in ImageJ. 
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Supplemental Figures 
Figure 1 
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Figure 2 
 
Appendix 
 120 
 
 
 
 
 
 
Paper 3 
Hofmann N., Galetskiy D., Rauch D., Wittmann T., Marquardt A., Griese M., and 
Zarbock R. (2015). Analysis of the proteolytic processing of ABCA3: identification of 
cleavage site and involved proteases. PloS One (accepted) 
 
1 
 
Analysis of the proteolytic processing of ABCA3: identification of 
cleavage site and involved proteases  
Nicole Hofmann1, Dmitry Galetskiy2, Daniela Rauch1, Thomas Wittmann1, Andreas 
Marquardt2, Matthias Griese1, and Ralf Zarbock1* 
 
1 German Centre for Lung Research, Dr. von Hauner Children’s Hospital, Ludwig-
Maximilians University, 80337 Munich, Germany 
2 Proteomics facility, University of Konstanz, 78547 Konstanz, Germany 
 
 
* Corresponding author 
E-mail: Ralf.Zarbock@med.uni-muenchen.de 
Phone 0049/(0)89/4400-57717 
Fax 0049/(0)89/4400-57715 
 
 
2 
 
Abstract 
Rationale 
ABCA3 is a lipid transporter in the limiting membrane of lamellar bodies in alveolar type II 
cells. Mutations in the ABCA3 gene cause respiratory distress syndrome in new-borns and 
childhood interstitial lung disease. ABCA3 is N-terminally cleaved by an as yet unknown 
protease, a process believed to regulate ABCA3 activity.  
Methods 
The exact site where ABCA3 is cleaved was localized using mass spectrometry (MS). 
Proteases involved in ABCA3 processing were identified using small molecule inhibitors and 
siRNA mediated gene knockdown. Results were verified by in vitro digestion of a synthetic 
peptide substrate mimicking ABCA3’s cleavage region, followed by MS analysis  
Results 
We found that cleavage of ABCA3 occurs after Lys174 which is located in the proteins’ first 
luminal loop. Inhibition of cathepsin L and, to a lesser extent, cathepsin B resulted in 
attenuation of ABCA3 cleavage. Both enzymes showed activity against the ABCA3 peptide 
in vitro with cathepsin L being more active. 
Conclusion 
We show here that, like some other proteins of the lysosomal membrane, ABCA3 is a 
substrate of cathepsin L. Therefore, cathepsin L may represent a potential target to 
therapeutically influence ABCA3 activity in ABCA3-associated lung disease. 
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Introduction 
ABCA3 is a member of the subclass A of the large ABC transporter family which 
comprises transporters involved in cellular lipid transport [1]. ABCA3 is strongly expressed 
in the lungs where it localizes to the outer membrane of lamellar bodies (LBs) in alveolar 
epithelial type II cells [2,3]. It transports phospholipids and cholesterol into the LB lumen and 
is essential for the biogenesis of LBs [4,5]. Mutations in ABCA3 cause an often fatal severe 
respiratory distress syndrome in new-borns and diffuse parenchymal lung disease in children 
(chILD) [6,7].  
To date, little is known about the cell biology of ABCA3. After folding in the ER and 
glycosylation in the Golgi apparatus, ABCA3 is trafficked to the endosomal compartment and 
finally reaches acidic, lysosome-derived multivesicular bodies, precursors of LBs [8]. The 
exact route ABCA3 takes remains elusive; for example, it is currently unknown whether it 
passes the plasma membrane. Interestingly, in immunoblots ABCA3 gives two protein bands 
with an apparent molecular mass of approximately 190 and 170 kDa, respectively [4,9]. We 
showed previously that the lower band arises by proteolytic cleavage at the N-terminus of 
ABCA3 [10]. In the same study, we also identified post-trans-Golgi acidic vesicles as the 
intracellular compartment of ABCA3 processing and provided evidence for the involvement 
of a cysteine protease. 
Since it can be expected that cleavage of ABCA3 has an effect on the protein’s 
function, the protease(s) involved the processing of ABCA3 represent a potential therapeutic 
target. Inhibition of the enzyme(s) in order to elevate the amount of ABCA3 may counteract 
diminished ABCA3 activity as a result of mutations or diminished expression due to disturbed 
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gene regulation. Therefore, the objectives of the present study were the identification of the 
protease(s) cleaving ABCA3 and of the precise cleavage site. 
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Materials and methods 
Cell culture 
A549 cells were obtained from DSMZ (Braunschweig, Germany). Cells were 
maintained in RPMI 1640 medium (Life technologies, Darmstadt, Germany) supplemented 
with 10 % FBS at 37°C and 5 % CO2. Stable transfection of A549 cells with pUB6-ABCA3-
WT vector was carried out as previously described [11]. Cleavage site mutations were 
introduced into pUB6-ABCA3-WT using the Q5 Site-Directed Mutagenesis Kit (NEB, 
Frankfurt/Main, Germany) according to the manufacturer’s instructions. For inhibitor 
experiments, cells were grown to confluence, trypsinized and seeded at 200.000 cells per 
6-well and grown for 48 h prior to treatment. For siRNA mediated knockdown, cells were 
trypsinized and cell suspension was adjusted to 200,000 cells / ml in RPMI medium with 
10 % FBS. 2 ml of cell suspension was then added to a mixture of siRNA (125 pmol / well; 
Life technologies) and Lipofectamine 2000 (8 µl / well; Life technologies) in OptiMEM (Life 
technologies) dispensed in 6-well plates. Cells were harvested after incubation with siRNA 
for 48 h. Scrambled siRNA (Life technologies) was used as control. 
Gel electrophoresis and immunoblot  
After harvesting by trypsination, cells were rinsed with PBS once and subsequently 
lysed with radioimmunoprecipitation (RIPA) buffer (0.15 M sodium chloride, 1 % Triton-X 
100, 0.5 % sodium deoxycholate, 0.1 % SDS, 5 mM EDTA and 50 mM Tris pH 8) containing 
complete protease inhibitor (Roche, Mannheim, Germany). The lysate was centrifuged for 
30 min at 1000 x g and 4°C. The protein concentration of the post-nuclear supernatant 
(= whole cell lysate) was determined with Bradford assay using BSA as protein standard. 15 -
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 30 µg of cell lysates in 4x LDS buffer (Life technologies) were loaded onto NuPage Mini 
Bis-Tris or Tris-Acetate gels (Life technologies). Following gel electrophoresis, proteins were 
visualized using Coomassie Brilliant Blue (Sigma-Aldrich, Steinheim, Germany) or 
transferred to PVDF-membranes (Millipore, Billerica, USA) and immunoblotted using anti-
HA-tag (Roche) and anti-β-actin HRP conjugate (Santa Cruz, Heidelberg, Germany). 
Chemiluminiscent signal was detected by ECL Detection Reagent (GE Healthcare, Freiburg, 
Germany) and analyzed by densitometry. 
RNA isolation/cDNA synthesis/quantitative real time PCR 
Cells grown to confluence in 6-well plates were washed once with PBS. Cells were 
harvested and total RNA was isolated with the High Pure RNA Isolation Kit (Roche, 
Mannheim, Germany) according to the manufacturer’s instructions. RNA concentrations were 
measured with a NanoDrop spectrophotometer (Thermo Scientific, Waltham, MA, USA). 
1 µg of total RNA was reversely transcribed into cDNA with the Tetro reverse transcription 
kit (Bioline, Luckenwalde, Germany). Quantitative real-time PCR was carried out using 
SensiFAST SYBR Hi-ROX Mix (Bioline) on an ABI 7900HT cycler (Applied Biosystems, 
Darmstadt, Germany). HPRT1 was used as housekeeper gene. For analysis of relative 
changes, data was analyzed according to the ΔΔCT method. 
In-gel digestion and peptide extraction 
Gel bands visualized with Coomassie Blue were excised, destained and digested with 
trypsin gold mass spectrometry grade (Promega, Madisson, USA) according to the 
manufactures’ protocol. Extracted peptides were subjected to LC-MS/MS analysis. 
 
7 
 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
and data analysis 
Peptide mixtures were separated using an Eksigent nano-HPLC (Eksigent 
Technologies, Dublin, USA) with a reversed-phase LC column (5 µm, 100 Å pore size C18 
resin in a 75 µm i.d. × 10 cm fused silica capillary; Acclaim PepMap100; Thermo Scientific, 
Waltham, USA). After sample injection, the column was washed for 5 min with 95% mobile 
phase A (0.1% formic acid) and 5% mobile phase B (0.1% formic acid in acetonitrile), and 
peptides were eluted using a linear gradient of 5% mobile phase B to 40% mobile phase B in 
65 min, then to 80% B in an additional 5 min, at 300 nL/min. Mass spectrometric analysis 
was performed on an LTQ-Orbitrap Discovery mass spectrometer (Thermo Fisher Scientific, 
Bremen, Germany) operated in a data dependent mode in which each full MS scan (m/z 200-
1,450) acquired in Orbitrap with resolution of R=30,000 (m/z 400) was followed by five 
MS/MS scans where the five most abundant molecular ions were dynamically selected and 
fragmented by collision-induced dissociation (CID) using a normalized collision energy of 
35% in the LTQ ion trap. Dynamic exclusion was allowed. 
Mascot database searching was performed using the Mascot Server 2.3 software 
(Matrix Science, London, UK); all tandem mass spectra were searched against the SwissProt 
and NCBInr human protein databases. Search criteria for tryptic digest mixtures included 
trypsin as an enzyme, one missed cleavage, methionine oxidation as variable modification and 
mass tolerances of 5 ppm for MS and 0.5 kDa for MS/MS. The results were filtered to a 5% 
maximal false discovery rate; peptide score cut-off of 15 was used. Identification of modified 
and non-specifically cleaved peptides was additionally performed by the Mascot error tolerant 
search. Presence/absence of ABCA3 sequence parts ware validated with Xcalibur software 
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(Thermo Finnigan, San Jose, CA, USA) using extracted MS ion chromatograms of the 
accurate peptide m/z values ±5 ppm related to corresponding peptide ions. 
In vitro analysis of products from cleavage of ABCA3 with 
cathepsins B and L 
Synthetic KYHLRFSYTRRNYMWTQTGSFFLKETEGWHTTSLFPLFPNPGPR 
peptide (HPLC purity 98%), comprising residues 151-194 of human ABCA3, was purchased 
from GenScript (Piscataway, USA). Peptide cleavages were performed with cathepsin B 
purified from human placenta (Sigma-Aldrich) and human recombinant cathepsin L 
(GeneTex, Irvine, USA) using single cathepsins or their combination. Peptide and cathepsins 
were mixed in 100 µL 10 mM ammonium acetate pH 4.5 to a final concentration of 20 µM for 
the peptide and 2 µM for either of the cathepsins. After 20 min incubation at 37°C samples 
were immediately analyzed by LC-MS/MS. 
Statistics 
Comparisons of multiple groups were done using one-way repeated measure 
ANOVAs with Tukey’s post hoc test. Results were presented as mean + S.E.M. of a 
minimum of three different experiments. P-values of less than 0.05 were considered 
statistically significant. All tests were performed using GraphPad Prism 5.0 (GraphPad 
Software, La Jolla, USA). 
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Results 
Mass spectrometric analysis reveals N-terminal cleavage region of 
ABCA3 
Protein cleavage site or region can be quantitatively determined using intensity ratios 
of tryptic peptides or their fragments in cleaved and non-cleaved protein forms [12]. We 
separate proteins of A549 cells transfected with pUB6-ABCA3-WT vector by gel 
electrophoresis, visualized them with Coomassie Blue, and analyzed by LC-MS/MS. ABCA3 
protein was identified in gel bands at 190 kDa and 170 kDa (Fig 1A). Profile analysis using 
highly accurate (±5 ppm) MS chromatograms for corresponding peptide ions revealed the 
presence of the C-terminal protein part comprising residues (175-1704) in both bands. Tryptic 
peptides from the N-terminal protein region (6-174) were detected only in the upper band. 
Parts of the ABCA3 protein sequence identified in 190 kDa and 170 kDa gel bands are 
presented in Fig 1B. Fig 1C illustrates the quantitative MS approach used for the 
determination of the cleavage region. The peptide intensity ratios (170 kDa / 190 kDa) was 
1.7±0.4 within the sequence (175-1704) and ~0 for the peptides (6-13), (115-121) and (162-
174) from the N-terminal region (Fig 1C). Remarkably, highly intense signals of doubly-
charged ions at m/z 819.885 and at m/z 811.887 identified as peptide 
162NYMWTQTGSFFLK174 with and without oxidation at Met164 were detected in 190 kDa 
band (Fig 2). These signals are completely missing in 170 kDa band. This observation 
provides evidence of N-terminal ABCA3 processing within the region between residues 162 
and 174. Due to the relatively high signal intensity of the peptide (162-174) we would have 
expected the signal (X-174, X-amino acid residue after the cleavage site of protein 
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processing) with significant intensity present only in N-terminally processed 170 kDa 
ABCA3. We have searched for signals with corresponding m/z values but could not find any. 
Therefore, from these experiments we propose ABCA cleavage after Lys174 or close to it. In 
this case, the peptide (X-174) is too small and lost during sample preparation or enrichment.  
Prediction of the membrane topology of ABCA3 suggests that the 
cleavage site is located in the vesicular lumen 
We used TOPCONS (http://topcons.net/) for consensus prediction of ABCA3 
membrane topology [13]. The prediction generated by TOPCONS is a consensus from five 
different topology prediction algorithms. The results of all five algorithms are in agreement 
with an outside orientation of the identified cleavage region, i.e. the region is located in the 
lysosomal lumen (Fig 3). 
Application of specific inhibitors suggests cathepsins L and B as 
ABCA3 processing enzymes 
From earlier studies, we knew that ABCA3 is N-terminally cleaved by a cysteine 
protease and that acidification of the vesicles ABCA3 resides in is necessary for cleavage to 
occur [10]. Based on this knowledge, we aimed to narrow down the list of proteases possibly 
involved by application of highly specific inhibitors. ALLM (N-Acetyl-Leu-Leu-Met-CHO) 
is an inhibitor of calpains I and II and also very potently inhibits cathepsins B and L [14]. 
ALLM almost completely abolished proteolytic processing of ABCA3 and lead to a 
prominent accumulation of the 190 kDa band, while the 170 kDa band became weaker (Fig 
4A). Since the identified cleavage site is located in the vesicular lumen, we reasoned that the 
protease(s) cleaving ABCA3 would have to be lysosomally located and active at acidic pH. 
The latter would exclude calpains. Since results with ALLM pointed to involvement of 
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cathepsin B and/or L, we applied inhibitors thought to be specific for cathepsin B and 
cathepsin L, respectively. Treatment of cells with the cathepsin B inhibitor L-trans-
expoxysuccinyl-Ile-Pro-OH propylamide methyl ester (CA-074Me; [15]) resulted in 
accumulation of the 190 kDa ABCA3 band when concentrations of at least 60 µM were used; 
the 170 kDa band remained unchanged (Fig 4B). The weaker effect of CA-074Me on ABCA3 
cleavage compared to ALLM suggests rather low activity of cathepsin B as an ABCA3 
cleaving enzyme. For ALLM and CA-074Me, the inhibitor concentrations used did not impair 
the general cell growth or fitness (data not shown). Incubation of cells with the cathepsin L 
inhibitor N-(1-naphthalenylsulfonyl-L-isoleucyl-L-tryptophanal (NapSul-Ile-Trp-CHO; [16]) 
did not result in accumulation of the 190 kDa band (Fig 4C). Inhibitor concentrations 
exceeding 40 µM lead to a disappearing of both bands, indicating that cathepsin L inhibition 
with NapSul-Ile-Trp-CHO has a stronger effect on cell viability than on ABCA3 production 
and processing. Our results gathered using protease inhibitors thus suggest cathepsin L and - 
to lower extend - cathepsin B as ABCA3-processing enzymes, but the action of cathepsin L 
could not be proven clearly due to the adverse effects on cell viability by specific inhibition of 
cathepsin L. 
siRNA mediated knockdown of cathepsins confirms involvement 
of cathepsins L and B 
To further verify ABCA3 processing by cathepsins, we used siRNA-mediated 
knockdown of cathepsin genes. To do this, we applied siRNAs directed against all cysteine 
proteases of the cathepsin family that had been identified in lysosomes [17]. This included 
proteases encoded by CTSB, CTSF, CTSH, CTSK, CTSL1, CTSL2, CTSO, and CTSS. As a 
control, we also used siRNA knockdown of CTSD (Asp protease). Gene knockdown was 
monitored using quantitative PCR and was considered successful when expression was 
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reduced by more than 70% (data not shown). Immunoblot performed on cell lysates collected 
48 h after siRNA transfection showed accumulation of the 190 kDa band as an indicator for 
inhibition of cleavage only in the case of CTSL1 (Fig 5). The effect was slightly enhanced 
when knockdown of cathepsin L and cathepsin B was performed simultaneously, indicating a 
possible additive action of both proteases. When we quantified protein bands to assess the 
ratio of 190 kDa to 170 kDa ABCA3 bands, we found significant increase of the band ratio in 
the case of CTSL1 alone and also for the combination of CTSL1 and CTSB (Fig 6). Thus, 
siRNA knockdown confirms the involvement of cathepsins B and L in the processing of 
ABCA3 and points to combined action of these proteases. 
MS analysis of ABCA3 peptide cleavage products demonstrates 
specific cleavage after Lys174 by cathepsin L  
To verify the ABCA3 cleavage by cathepsins L and B, we performed proteolytic 
digestion of a peptide comprising residues 151-194 of ABCA3 with cathepsins L and B at 
acidic conditions (pH 4.5) and analyzed the cleavage products by LC-MS. Triply-charged ion 
at m/z 761.711 corresponding to the ABCA3 sequence (175-194) related to the cleavage after 
Lys174 was the most prominent signal appearing during incubation of the peptide with 
cathepsin L alone and in combination with cathepsin B. High cleavage specificity of cathepsin 
L for the peptide within the ABCA3 processing region is illustrated in Fig 7. Specificity and 
cleavage efficiency of cathepsin B was significantly lower in comparison to cathepsin L. 
Major cathepsin B cleavage products were the peptides (172-194) and (168-194) related to the 
cleavages after Phe171 and Gln167, respectively, in almost equivalent amounts. Cleavage 
patterns resulting from the combination of cathepsins L and B suggest sequential action (data 
not shown). Our study thus reveals highly specific ABCA3 processing by cathepsin L after 
Lys174. 
13 
 
Inactivation of putative cathepsin L cleavage site inhibits ABCA3 
processing 
Having identified cathepsin L as the major protease responsible for cleavage of 
ABCA3 as well as its cleavage site, we aimed to abolish cleavage by abrogating substrate 
recognition. Since it is known that both amino acid residues that precede the actual cleavage 
site are crucial for substrate recognition, we replaced Leu173 and Lys174 of ABCA3 with 
alanine residues. This operation resulted in prominent accumulation of the upper ABCA3 
band (Fig 8), indicating inhibition of processing and confirming correct identification of the 
cleavage site. 
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Discussion 
In the present study, we show that ABCA3 is proteolytically cleaved by cathepsin L 
and to a lower extent also by cathepsin B. We also identified the exact cleavage site of 
cathepsin L which is located after Lys174. 
We have previously shown that ABCA3 is N-terminally cleaved in LAMP3-positive 
vesicles which are supposed to be lysosome-related organelles [10]. We now report 
identification of the precise cleavage site. According to the predicted membrane topology of 
ABCA3 (Fig 2), this site is located in the proteins’ first large extracellular loop. Therefore, 
this loop is oriented towards the acidic lumen of the vesicles and is accessible to proteases of 
the lysosomal matrix. This finding is in concordance with our previous report that ABCA3 is 
cleaved upon reaching LAMP3-positive vesicles and that cleavage is blocked by inhibition of 
vesicle acidification [10]. It can be speculated that the localization of the cleavage site in the 
largest lumenal loop of ABCA3 – which is similar to CLN7 – favours steric access for 
proteolytic enzymes in the lysosomal lumen [18]. The first lumenal loop also contains two N-
linked glycosylation sites (Asn124 and Asn140) in vicinity of the cleavage site [19]. N-linked 
glycosylation of these sites in ABCA3 may limit the rate of proteolysis as it does in the cases 
of LAMP-1, LAMP-2, and also CLN7 [18]. 
We had also shown earlier that cleavage is blocked by E-64, an inhibitor of cysteine 
proteases. Based on these results, it was clear that the protease(s) involved in the processing 
of ABCA3 had to be lysosomal cysteine proteases active at acidic pH. Using a combined 
approach consisting of specific protease inhibitors and siRNA mediated gene knockdown, we 
show here that cathepsin L and B are likely involved in ABCA3 processing. However, the 
effect seen in the case of CA-074Me required rather high inhibitor concentrations, implicating 
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that the specific activity of cathepsin B against ABCA3 is not very high. This assumption is 
corroborated by the results of in vitro digestion. Moreover, although CA-074 was thought to 
be specific for cathepsin B, it turned out that the cell permeable CA-074Me also inhibits 
cathepsin L to some extent [20]. Therefore, it cannot be used to reliably distinguish between 
cathepsin B and cathepsin L. The specific cathepsin L inhibitor NapSul-Ile-Trp-CHO 
prevented formation of both ABCA3 forms, a finding that is in concordance with earlier 
reports that NapSul-Ile-Trp-CHO causes a dose-dependent suppression of cell proliferation 
and cell-death in SaOS2 cells at concentrations of 40 µM [21]. It is thus possible that when 
treated with NapSul-Ile-Trp-CHO, A549 cells did not survive long enough to accumulate the 
190 kDa ABCA3 form. Specific inhibition of cathepsin L seems to be a general problem if 
cancer cells are used; a strong inhibitory effect on cancer cell proliferation was reported also 
for other specific chemical inhibitors and neutralizing antibodies of cathepsin L [22, 23]. 
However, we reasoned that given the results from siRNA knockdown and in vitro digestion 
experiments, it was not necessary to test further inhibitors. Taken together, the results of small 
molecule inhibitors and siRNA knockdown indicate that both cathepsin L and cathepsin B are 
possibly involved in ABCA3 processing. However, the moderate effect of CA-074Me and the 
in vitro digestion of ABCA3 peptide indicate that the activity of cathepsin B towards ABCA3 
is much lower than that of cathepsin L. It is thus questionable whether cleavage of ABCA3 by 
cathepsin B is physiologically relevant.  
Cleavage of ABCA3 is a further example for a highly specific function of cathepsins. 
While they were long believed to perform unspecific bulk proteolysis, it has now become 
evident that cathepsins also carry out specific non-redundant in vivo functions [24]. It has also 
been discussed that expression of ubiquitous cathepsins in specialized cells – which certainly 
applies to alveolar epithelial type II cells – may indicate a highly specific function for a rather 
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nonspecific protease [25]. Indeed, cathepsin L was shown to be involved in the processing of 
cathepsin D in A549 cells [26]. There are a few examples of lysosomal membrane proteins as 
cathepsin L substrates [27]. In the case of cathepsin L, its involvement in the processing of 
DIRC2 and CLN7 has been demonstrated [18,28]. CLN7 was the first example of a disease-
associated lysosomal membrane protein that is processed by cathepsin L [18]. 
Analysis of peptide fragments using mass spectrometry showed that the peptide was 
cleaved by cathepsin L after Lys174 in concordance with the cleavage site we had found for 
full-length ABCA3 in living cells. For cathepsins, it was found that S2 is the primary 
specificity-defining site [29]. The respective residue in the case of ABCA3 would be Leucine 
which is accepted at this position by most lysosomal cysteine proteases. Indeed, Leu173 and 
Lys174 seem to be important for the recognition by cathepsin L as exchanging both residues 
for alanine resulted in a marked inhibition of cleavage (Fig 7). The observation of in vitro 
cleavage by cathepsin L also implies that ABCA3 is a direct substrate of cathepsin L rather 
than of a downstream protease activated by cathepsin L. 
Cathepsin L deficiency in mice is not associated with lung disease [24]. Although it 
cannot be concluded that the same is necessarily true in humans, no lung disease associated 
with mutations in the cathepsin L gene has been observed so far. Thus, it seems that cathepsin 
L-mediated cleavage is not critically required for functional activation of ABCA3. This would 
support the hypothesis that full-length ABCA3 is functionally active and that proteolytic 
cleavage serves to regulate ABCA3 levels rather than activating the transporter. However, it 
can be expected that a certain level of ABCA3 is needed for sufficient biosynthesis of 
lamellar bodies and secretion of surfactant into the alveolar space. Since the amount of 
ABCA3 depends on the rates of synthesis and degradation, it is reasonable to speculate that 
disturbances of the steady state may negatively affect surfactant homeostasis and ultimately 
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lead to disease. On the other hand, when ABCA3 degradation was inhibited by targeting 
cathepsin L activity, a positive effect on ABCA3 activity could be expected. Interfering with 
the activity of cathepsin L in alveolar epithelial type II cells may thus represent an approach 
to ameliorate ABCA3 function in patients suffering from lung disease due to ABCA3 
haploinsufficiency [30]. 
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Figures 
Fig 1. Analysis of ABCA3 cleavage region. A: ABCA3 containing gel bands were excised, 
digested with trypsin and analysed. B: Partial sequences of unprocessed (190 kDa) and 
processed (170 kDa) ABCA3 forms identified by LC-MS/MS. Identified sequence parts of 
ABCA3 precursor protein including HA-TAG with spacer (shown in blue) are underlined. 
Sequences identified only in unprocessed form and absent in processed form are shown in 
red. Cleavage region (162-174) is highlighted in yellow. C: Peptide intensity ratios from MS 
ion chromatograms (three measurements), leading to the predicted cleavage region 
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Fig 2. Partial sequence (162-174) is present in unprocessed ABCA3 and missing in 
processed protein form. A: Intensity profiles of an m/z range corresponding to the 
monoisotopic peak of the doubly-charged ion at m/z 819.885 (m/z window ±5 ppm) for 
190 kDa and 170 kDa gel bands acquired in Orbitrap. B: Identification of the ABCA3 tryptic 
peptide comprising amino acid residues 162–174 of the precursor protein and containing 
methionine sulfoxide at position 164. MS/MS spectra after CID fragmentation measured in 
the LTQ ion trap are shown. Major b and y ions are labelled on the spectra and all fragment 
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ions obtained are marked on the identified sequence. The ion at m/z 811 corresponds to the 
loss of water from the parent ion. 
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Fig 3. Predicted membrane topology of ABCA3 and localization of the identified 
cleavage site. A) Membrane topology of ABCA3 as predicted by different algorithms (top) 
and consensus prediction generated by TOPCONS (bottom) [13]. B) Model of ABCA3 in the 
vesicular membrane generated based on the TOPCONS prediction. Scissors indicate the 
identified cleavage site in the first extracellular loop (EL1). 
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Fig 4. Effects of protease inhibitors on ABCA3 processing. Cells were treated with ALLM 
(N-Acetyl-Leu-Leu-Met-CHO) (A), CA-074 (L-trans-Expoxysuccinyl-Ile-Pro-OH 
propylamide) methyl ester (B), and N-(1-naphthalenylsulfonyl-L-isoleucyl-L-tryptophanal 
(C), and cleavage of ABCA3 was assessed by Western blotting. 
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Fig 5. Effect of knockdown of single proteases on ABCA3 processing. Expression of 
lysosomal cathepsins was silenced using siRNA mediated knockdown and ABCA3 cleavage 
was assessed by Western blotting. Experiments were performed thrice, every time in 
triplicates. Representative Immunoblots are shown. 
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Fig 6. Quantitative analysis of the inhibition of ABCA3 processing. The ratio of 190 kDa 
to 170 kDa ABCA3 bands points to an inhibition of processing by knockdown of either 
CTSL1 alone or CTSL1 in combination with CTSB. Accumulation of the 190 kDa ABCA3 
species is a result of inhibition of proteolytic cleavage due to cathepsin knockdown. ** 
p < 0.01; *** p < 0.001. 
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Fig 7. Cathepsin L cleaves ABCA3 peptide preferentially after Lys174. Shown are signal 
intensities of C-terminal cathepsins L and B cleavage products of ABCA3 peptide (151-194) 
within the sequence 162NYMWTQTGSFFLK174 analyzed by LC-MS/MS. Extracted MS ion 
chromatograms of the accurate m/z values ±5 ppm related to the corresponding peptide ions 
(peak areas) from three experiments were used for the diagram. 
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Fig 8. Mutation of potential Cathepsin cleavage sites. Amino acids forming potential 
cleavage sites were replaced by alanine residues using site directed mutagenesis. Lane 1: cells 
transfected with empty vector; lane 2: wild type ABCA3; lane 3: deletion of the first 174 
amino acids of ABCA3; lane 4: 173LK174 > AA. 
 
 
 
 
